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Drug discovery is an important field of research in the biotechnology and 
pharmaceutical industries. Plasma membranes are rich in drug targets and other 
proteins responsible for cell signaling, transport, signal transduction, and other 
cellular functions. Information obtained about these proteins, and the pathways they 
participate in, helps to facilitate the drug discovery process. Although these plasma 
membrane proteins play important roles in cellular function, they are usually 
expressed in very low abundance and are therefore hard to identify and analyze. 
Comparative proteomic analysis of plasma membranes in different types of cells or 
different disease states of the same cell or tissue type can help to design targeted 
therapies specific to particular cell or tissue types and can be used in the identification 
of biomarkers for early disease detection. In order to be able to identify proteins in the 
plasma membrane it is important to start out with a plasma membrane fraction that is 
free of contamination from other more abundant proteins from other portions of the 
cell. 2D gel electrophoresis is the primary protein separation tool for use with 
proteomics and drug discovery, however, the inability of membrane proteins to be 
separated using isoelectric focusing, which is the first step in the 2D gel protocol, 
excludes 2D gel electrophoresis as a viable technique for the separation of membrane 
proteins. 
This thesis develops and evaluates a method to identify proteins found in the plasma 
membranes of mammalian cells using a modified form of the cationic colloidal silica 
technique for plasma membrane isolation combined with analysis of these proteins 
using mass spectrometry. This method is then used in combination with metabolic 
stable isotope labeling to identify protein expression changes between the 
mitoxantrone drug susceptible and drug resistant MCF-7 breast cancer cell lines.
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Chapter 1: Introduction and Overview
Reproduced in part with permission from: Rahbar, A., Fenselau, C. (2004). 
Integration of Jacobson's Pellicle Method into Proteomic Strategies for Plasma 
Membrane Proteins. J Proteome Res. Web Release Date: 13-Oct-2004. Copyright 
2004 American Chemical Society.
A. Cancer and Drug Resistance
According to the National Vital Statistics Report, in the United States, cancer has 
become the second leading cause of death among all ages, and was found to be the 
leading cause of death for those between the ages of 44 and 65.1 As individuals
increase in age, their chances of developing some form of cancer increases. Despite 
new therapies and lower death rates for cancer sufferers, the incidence of cancer is 
predicted to increase in the coming years due to the rise in average expected human 
lifespan and subsequent increasing aging population, and this is predicted to increase 
the burden of cancer on our country.2
Common cancer treatments are chemotherapy, radiation therapy, and surgery, and 
these treatments are often used in combination with one another depending upon the 
progression and type of cancer diagnosed.3; 4; 5 Drugs that target DNA are among the 
most common type used in chemotherapy. Some of the more common drug classes 
are alkylating agents and antitumor antibiotics. The mechanisms these drugs use
include crosslinking DNA, inducing DNA double strand breaks, intercalating into
DNA, and inhibiting topoisomerases I and I. 6 The overall desired effect of these 
actions is to damage the DNA, interfere with the cell cycle, and ultimately induce cell 
death. In recent years, innovative therapies which are more specific, such as agents
that target DNA secondary structures, agents that target protein-D NA complexes, and 
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sequence specific DNA agents have been in development in order to more 
specifically target tumor cells.6
Drug resistance in cancer patients is becoming an increasingly common problem. A
patient who may have responded favorably to initial treatment with a particular anti-
cancer agent may have little or no response to a secondary treatment with not only the 
previous drug used, but also to other drugs not yet administered which can be
structurally unrelated and need not have common mechanisms of action to the drug 
used at the onset of the illness.7 This phenomenon is called acquired drug resistance 
or multi-drug resistance.7 This multi-drug resistance is usually attributed to protein 
abundance changes of several classes of proteins.7
Figure 1 shows a representation of some of the general mechanisms of drug 
resistance used by the cell.7 One way resistance is achieved is by decreasing the 
effective concentration of the drug in the cell. This is facilitated by decreased influx 
or increased efflux of chemotherapeutic agents by transporters in the plasma 
membrane of the cell. One method of increased efflux is to overexpress
efflux transporters such as P-glycoprotein (Pgp) or Multidrug Resistance Proteins
(MRP), which pump agents out of the cell.8; 9; 10 Another method of decreasing the 
effective concentration in the cell is to compartmentalize the agent for later 
processing or removal from the cell. These mechanisms of drug resistance work well 

















Figure 1: Mechanisms of Chemoresistance (Gottesman et al).7
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allowed to accumulate in the cell, another mechanism of drug resistance is to increase 
the expression of phase I and phase II detoxifying enzymes such as Glutathione-S- 
transferase (GST) and Cytochrome P450.11; 12; 13; 14 The cell can also increase
expression of proteins which block apoptosis and allow the cell to proliferate in its
mutated state. If the DNA damaging agent happens to elude all of the above 
mentioned mechanisms, the DNA damage done by the drug can be repaired by an 
increase in the expression of DNA repair proteins and the apoptotic pathway will not 
be activated.7 So there are many possible cellular mechanisms working individually 
or in concert with one another using naturally occurring proteins and pathways which 
can be induced or overexpressed in order to achieve drug resistance.
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B. Proteomics and Mass Spectrometry
Where a genome is the ensemble of genes possessed by an organism, a proteome can 
be described as the protein complement to the genome of that particular organism, or 
put simply, the proteome is the inventory of proteins which are being expressed by an 
organism under a particular set of conditions at a particular moment in time. Genomic 
data has a wide variety of uses and is both versatile and robust. Even before the 
sequencing of the human genome, genomic information could be used for 
identification using DNA fingerprinting. With the recent completion of the human 
genome sequence, we have more information available to us that can potentially help 
in the prevention and treatment of diseases. DNA microarrays are currently being 
used to study mRNA expression in different disease states, and this technique may 
one day be used by physicians to make quick diagnoses of genetic disorders and
diseases.15 However, post translational modifications, protein half-lives, and other 
protein processing events make it difficult to correlate mRNA expression with protein 
expression.15; 16 For this reason determining protein expression levels directly can be
a more accurate way to compare relative protein abundances.16 Unfortunately, unlike 
DNA, which can be amplified by PCR,proteins cannot be amplified and detection is
limited by their in vivo abundance, and unlike the genome, which is static, the 
proteome is dynamic and is dependant on various factors such as environmental 
stimulation and life cycle. It has been estimated that there are approximately 30,000 
predicted genes in the human genome.17 Taking into account RNA splice variants, 
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post translational modifications, and other post processing events, these genes are 
estimated to produce over 200,000 distinct proteins.18
The information made available by this genomic data can help in the field of 
proteomics. Experimental data may be compared to theoretical data calculated from 
an organism’s genome to identify hypothetical proteins which have not been 
previously identified or characterized. Databases searched using bioinformatics 
programs often incorporate both genomic and proteomic data from previously 
characterized proteins. 
When conducting any proteomic analysis, one is more likely to observe proteins
expressed in low abundances if one minimizes the complexity of the sample. This is 
especially true if the target is a minor component of the sample source. For this 
reason, often one of the first steps in a proteomic analysis of a eukaryotic system is 
sub-cellular fractionation of the cells, whereby the components of the cell are 
separated into their individual organelles or compartments. This type of proteomic 
study has been called organelle-based proteomics.18 Table 1 shows a list of the 
subcellular components of an epithelial cell and what percentage each component 
comprises of the total cell volume.18 By separating organelles, chances are maximized
for identification of proteins from organelles which make up a very small fraction of 
the cell, such as the golgi body or the plasma membrane. Without this sub-cellular 
fractionation, identification and analysis of proteins from whole cell lysates would 
only give information on the group of proteins which were the most abundant. 
7









Table 1: Breakdown of the subcellular components of an epithelial cell.18
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Sometimes, as with the cytosolic sub-cellular fraction, the sample is still too complex 
to analyze some of the lower abundance proteins. Further separation may be required 
using an HPLC method such as reverse phase, size exclusion, or ion exchange
chromatography. Another example of further fractionation would be to separate the 
soluble and insoluble fractions of a closed organelle such as the nucleus or 
mitochondria, which both have insoluble proteins in their membranes and soluble 
proteins in their aqueous interiors. Because of the limited dynamic range of proteomic 
techniques, sub-cellular fractionation can help to improve the number of proteins 
identified and characterized in samples of interest.19; 20
Mass spectrometry was first conceptualized in 1897 by Sir Joseph J. Thomson.21
Since then mass spectrometry has become a versatile tool of critical importance in the 
field of biological research. Mass spectrometry does not actually measure the 
molecular mass of a molecule. It measures the mass/charge ratio of that species. In 
order for the molecular species to be observed it must first be ionized. Some common 
ionization techniques used are chemical ionization, fast atom bombardment, and 
electron ionization, but for the purposes of proteomics and the analysis of most 
biological samples, matrix-assisted laser desorption/ionization (MALDI) and 
electrospray ionization are the most common ionization techniques used.22; 23; 24; 25; 26
These techniques are soft ionization techniques which allow the molecular species to 
become charged without much non-facilitated fragmentation of the parent species. 
These techniques also work well with biological samples of higher molecular masses.
9
MALDI ionization is a technique that uses a molecular matrix that can absorb energy 
from a laser. A laser is directed at a cocrystallized mixture of peptides or proteins and
matrix, and the matrix absorbs the energy from the laser, causing both the matrix and 
the sample to be transferred to the gas phase. The mechanism of ionization by 
MALDI is not clearly understood, but the result is that the sample is ionized by H+
transfer in the plume resulting from the absorbance of the laser energy by the 
matrix.22; 23; 27; 28 Once the sample is ionized in this manner it is moved through a 
strong electric field to a mass analyzer (Figure 2).27; 28 Most of the ions created using 
this technique are singly charged.
Unlike MADLI, in electrospray ionization the sample starts in the liquid phase rather 
than the solid phase. The sample is usually placed in a denaturing acidic 
aqueous/organic solution before ionization, typically in a ratio of 50:50:2 of methanol, 
deionized water, and acetic acid respectively. The acetic acid aids in protonation of 
the sample while the methanol aids in the evaporation of the liquid phase. If the 
sample of interest is to be observed in its non-denatured state then an aqueous 
solution such as ammonium bicarbonate can be used in place of the denaturing 
methanol/water/acetic acid solution. Producing a fine spray of this sample
of highly charged droplets in the presence of a strong electric field creates ions of the 
sample in the gas phase. A curtain of nitrogen gas helps to facilitate the evaporation 
of the liquid and once the samples are ionized, the sample is moved into the mass
10
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Figure 3: Schematic of the electrospray ionization method
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analyzer.25; 26; 29; 30 Electrospray ionization creates predominantly multiply charged 
species, which allows the analysis of high molecular weight compounds normally 
beyond the range of detection of the mass spectrometer. 
There are two proteomic approaches that are used for the analysis of pr oteins using 
mass spectrometry. The “top-down” approach involves the measurement of intact 
protein masses using advanced mass spectrometers. The information obtained from 
this type of analysis is often useful in the determination of post-translational 
modifications of proteins. The intact proteins can then be fragmented and the peptides 
resulting from this fragmentation can be analyzed to obtain sequence information 
which can aid in the identification of the protein. This fragmentation is achieved by
collisional induced dissociation (CID), which will be discussed later.
The second proteomic approach used for the analysis of proteins is sometimes called 
the “bottom-up” approach. In this method, intact proteins are subjected to enzymatic 
digestion and/or chemical cleavage, and the resulting peptides are then characterized 
using mass spectrometry. The information obtained from the analysis of these 
peptides using mass spectrometry is then used for protein identification and analysis. 
While the “bottom-up” technique is by far the more commonly used of the two
techniques, experiments have been performed using them in combination with one 
another, integrating the strengths of each into the proteomic analysis.31
One of the more common ways to analyze proteins using the “bottom-up” method is 
to digest the protein with a proteolytic enzyme and determine the molecular masses of
13
the resulting peptides using mass spectrometry. The set of peptide masses, along with 
other information such as the enzyme used and the species of origin if known, is 
searched against a protein database. The proteins are theoretically digested in silico
(by the computer) and the resulting sets of molecular masses are compared to the 
experimental sets. From this comparison a list of possible proteins is generated with 
scores and probabilities to determine the confidence of the identification.32; 33
Proteins may undergo many post-transcript processing and posttranslational 
modifications, which make it difficult to predict molecular protein masses from its 
corresponding genomic DNA sequences. Obtaining a peptide mass fingerprint from 
proteins with post-translational modifications is still possible due to the fact that the 
intact protein is cleaved into small segments that may not contain these post 
translational modifications and there are usually enough unmodified peptides to 
obtain an identification. 
A high percentage of sequence coverage is needed to obtain a reliable peptide mass 
fingerprint. In a situation where a positive identification cannot be obtained, 
microsequences from a few peptides can be provided by tandem mass spectrometry 
(MS/MS) for protein identification. An initial survey scan is obtained to determine 
the masses of the peptides introduced into the mass spectrometer and the intensities of 
their ions.
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A peptide ion is selected from this set of peptides and allowed to pass through a mass 
filter and into a collision cell while all other masses are excluded. This peptide is then 
allowed to collide with an inert gas such as nitrogen or argon to confer vibrational 
excitation and induce fragmentation. This procedure is called collision induced 
dissociation or CID. Typically, ions are moving with low kinetic energy and the low 
energy collisions produce limited fragmentation along the polyamide backbone. Most 
of the fragmentation occurs at the amide bonds, with the predominant species from 
this fragmentation being b ions, where the charge is retained on the N-terminal 
portion of the peptide after fragmentation, and y ions, where the charge is retained on 
the C-terminal portion of the peptide after fragmentation (Figure 4). 
The masses of fragment ions obtained by tandem mass spectrometry provides 
information about the amino acid sequence of the peptide in question. By determining 
the mass difference between adjacent y or b ions, the specific amino acids which 
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Figure 5: Tandem mass spectrum of a doubly charged peptide with an m/z of 713.36.
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Protein identification can be obtained using this sequence information in two ways. 
An amino acid sequence tag may be obtained by identifying 4 or more amino acids in 
the observed peptide that are in sequence. This information, along the mass of the 
parent ion, the mass of the peptide on the N-term and C-term sides of the sequence 
tag, and the enzyme used for cleavage is then entered into a protein database and a list 
of probable protein identifications is generated by comparison against known peptides 
from this protein database. The identifications are then given with individual scores 
and probabilities.33 Protein identification can also be obtained by comparing the 
MS/MS fragmentation spectrum directly with theoretical MS/MS spectra generated
for peptides in a protein database. Protein identifications are then generated with 
scores and probabilities as before.33 For organisms with genomes which have been 
sequenced, this mass spectrometry data may be used to compare with theoretical 
proteins predicted from the DNA sequence information.
18
C. Protein/Peptide Separation and Enzymatic Digestion
As protein mixtures increase in complexity, the analysis of proteins in the sample 
becomes more difficult, and the likelihood of identifying or analyzing less abundant 
components of these mixtures decreases. One way to overcome this obstacle is to use 
some protein separation technique upstream from the mass spectrometry analysis. 
Separation in this manner  is based on the physical properties of individual proteins 
such as size, charge, or affinity.
Historically, one of the most common ways to separate proteins is to perform an 
SDS-PAGE analysis.  Proteins are placed in a buffer containing 2% SDS. The SDS 
both denatures the proteins and associates tightly with them and therefore gives each 
protein a large negative charge. They are then loaded into wells on a polyacrylamide
gel. The gel is placed in a buffer containing SDS, and an electric current is applied to 
the gel. Because all of the proteins have a net negative charge, the electric current 
will separate the proteins based on their size or Stokes radii.34  By changing the 
percentage of the polyacrylamide in the gel, separations may be optimized to increase 
the resolution for proteins of either low, medium, or high molecular weights. A good
way to look at all protein mass ranges without sacrificing the resolution of a particular 
mass range is to use a gel with a continuous or discontinuous polyacrylamide 
percentage gradient such as 4-15%.
There are some drawbacks to this technique. The resolution of proteins from 
complex mixtures is poor and only rudimentary separation is obtained. Proteins can 
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aggregate in the sample wells and subsequently not migrate into the gel. Membrane 
proteins sometimes smear due to incomplete or heterogeneous incorporation of 
SDS.35; 36; 37 Having mentioned these limitations, there are also some advantages to 
this technique. The technique is well established and widely used. SDS-PAGE also 
has a high loading capacity. Although membrane proteins do not migrate in well 
behaved tight bands as their soluble counterparts do, separation of membrane proteins 
is still attained using this technique. 
Another gel-based technique is 2 dimensional gel electrophoresis (2DGE). 2DGE 
separates proteins not only by their size but by their charge, or isoelectric point (pI). 
The pI of a protein is the pH at which the net charge of the protein is zero. The 
technique of separating proteins by their pI is called isoelectric focusing (IEF). 
Membrane proteins are poorly represented when separated by 2D gel 
electrophoresis.38; 39; 40 This is predominantly due to their incompatibility with the IEF 
step. Membrane proteins require high concentrations of detergents to remain soluble 
in solution and detergents interfere with the IEF step. Membrane proteins also tend to 
precipitate at their pI and do not enter the 2nd dimension SDS-PAGE step. 
Another way to separate mixtures of proteins and peptides is to use high performance 
liquid chromatography (HPLC). This is a non-gel based method that can separate 
proteins based on their size, charge, hydrophobicity or other physical properties. 
There are two phases in HPLC; a stationary phase, and a mobile phase. The stationary 
phase is made up of material that has an affinity for a particular physical or chemical 
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property of proteins. The mobile phase is made up of organic or aqueous solvents,
which flows through the stationary phase. The mobile phase is changed during the 
course of the chromatographic experiment to increase or decrease the affinity of the 
sample for the stationary phase. Using this technique one can separate complex 
mixtures of proteins and peptides into pure components or smaller subsets that can be 
more easily analyzed. Some of the more common forms of chromatography used for 
the separation of proteins and peptides are size exclusion chromatography (SEC), 
which separates components based on their size, ion exchange chromatography (IEC), 
which separates components based on their charged state, and reverse phase 
chromatography (RPC), which separates components based on their polarity. 
As stated earlier, the vast majority of proteomic analyses are done using the “bottom-
up” approach. Therefore, the protein or proteins of interest must be cleaved with an 
enzyme or chemical in order to obtain peptides for the mass spectrometry analysis. 
One of the ways this is achieved is to first separate the proteins using some gel- based 
method such as SDS-PAGE. Following protein separation, the protein or proteins are 
excised from the gel using a scalpel or a robot to segment the desired area of the gel. 
This can be a protein gel spot, such as one obtained from a 2D gel, or a protein gel 
band, such as the type obtained from an SDS-PAGE experiment. Because of the high 
resolution obtained from 2DGE, the protein gel spots usually contain only 1 protein.
Unfortunately, due to the low resolving power of SDS-PAGE, protein gel bands 
obtained from SDS-PAGE gels  rarely contain only 1 protein and may often contain 
more than 10 depending on the size of the band excised from the gel. 
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Following the excision of the protein from the gel, the excised gel piece is then 
washed several times with aqueous and organic solvents to remove any excess salts or 
detergents from the gel that would interfere with the digestion process. Following this,
the gel piece is placed in a solution containing dithiothreitol to reduce disulfide bonds. 
Next the gel piece is placed in a solution of iodoacetamide to alkylate the reduced 
cysteines so they do not reform disulfide bonds. Following this, the gel piece is 
dehydrated, and rehydrated in a solution containing the proteolytic enzyme trypsin
and allowed to incubate overnight at 37ºC. By performing this procedure, the trypsin 
can enter the gel piece, bind the protein of interest and cleave the protein while it is 
still embedded in the gel matrix. Peptides are recovered from the gel pieces using 
acidified water and organic solvents and the extracted peptides are then analyzed by 
mass spectrometry.
Another “bottom-up” strategy for the analysis of proteins using mass spectrometry is 
to digest the proteins in-solution before analysis by mass spectrometry. This can be 
done in two different ways. Intact proteins can be fractionated using one or more of 
the chromatographic techniques mentioned earlier. These fractions can then be 
digested in a buffered enzymatic solution and analyzed by mass spectrometry using 
one of the previously describes methods. Complex mixtures of proteins can also be 
digested without any pre-fractionation and the resulting peptides can then be 
separated using one or more of the previously described chromatographic techniques. 
Most commonly a 2 dimensional separation of a peptide mixture consists of an initial 
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separation by ion exchange chromatography. After that each of the fractions obtained 
is then separated by reverse phase chromatography and analyzed by mass 
spectrometry.41 This technique is often called “shotgun” proteomics. By using this 2 
dimensional separation technique, which is sometimes automated, complex mixtures 
of peptides can be resolved and many proteins identified, including some of the less 
abundant ones. 
Multidimensional chromatographic separation steps and analysis using mass 
spectrometry can be performed separately or the liquid chromatography steps can be 
coupled directly to a mass spectrometer (LC-MS). The peptides or proteins elute 
directly from the liquid chromatography instrument into the mass spectrometer for 
analysis and sophisticated software is used to analyze the samples in real time. This 
type of analysis can be done both with proteins digested in-solution or with proteins 
that have been previously separated by any gel-based method and subjected to in-gel 
digestion to recover the peptides. Using LC-MS to analyze peptides recovered from 
SDS-PAGE gels can allow the characterization of hundreds of proteins from a single 
gel, making this a very powerful tool for analysis.
23
Chapter 2: Plasma Membrane Isolation Technique
Reproduced in part with permission from: Rahbar, A., Fenselau, C. (2004). 
Integration of Jacobson's Pellicle Method into Proteomic Strategies for Plasma 
Membrane Proteins. J Proteome Res. Web Release Date: 13-Oct-2004. Copyright 
2004 American Chemical Society.
A. Membrane Protein Overview
Biological membranes are made up of lipids and proteins. These lipids form a 
bilayer, with polar head groups associated with the aqueous cellular environments 
and non-polar tail groups associated with each other creating a hydrophobic 
environment within the membrane. There are different types of membrane proteins 
associated with biological membranes. Figure 6 shows some of these: 42
• Single pass transmembrane proteins – proteins which pass from one side of 
the membrane to the other once.
• Multiple pass transmembrane proteins – proteins which pass from one side 
of the membrane to the other more than once.
• Lipid linked membrane proteins – proteins which have lipids covalently 
linked to them which anchor the protein to the membrane.
• Peripheral membrane proteins – Proteins which are associated with the 
membrane or other proteins in the membrane but are not inserted into it or 
covalently bound to it.
Membrane proteins can also be combinations of these types, such as a protein 
which is both lipid linked and transmembrane spanning, or proteins partially 
inserted into the membrane without passing completely through to the other side. 
24
Biological membranes are fluid, and membrane proteins are free to move about the 
membrane.42 Membranes act as a two dimensional solvent for membrane
proteins the way the cytoplasm acts as a three dimensional solvent for soluble 
proteins. In prokaryotes, the only membrane is the plasma membrane so they 
contain no internal membrane organelles. Eukaryotes, on the other hand, contain 
internal organelles with membranes. These internal membranes serve to 
compartmentalize these structures in the cell, which have their own functions. 
This dissertation outlines a method for the identification and characterization of 
proteins found in the plasma membranes of cell cultures. The first step in this 
analysis is the subcellular fractionation of a plasma membrane fraction. As is stated 
in the previous chapter, the plasma membrane makes up only a small percentage of 
the cell and its isolation can be difficult. In eukaryotes there are internal membranes 
present in much higher abundances than the plasma membrane and these need to be 
separated. 
Subcellular fractionation before proteomic analysis can greatly increase the number 
of protein identifications by simplifying the complexity of the sample used for 
analysis. The cytosol is the easiest of these fractions to isolate and also the most 
abundant.18 Other organelles such as the nuclei and mitochondria are easily isolated 














Figure 6: Different types of membrane proteins
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their own membrane and they are readily separated by centrifugation.43 Other 
organelles such as the endoplasmic reticulum, the Golgi apparatus, and the plasma 
membrane are more amorphous and harder to separate. Some membrane isolation 
techniques recover all internal membranes together after cell lysis.44; 45 Since the 
total membrane fraction constitutes a large portion of the cell volume, and the 
plasma membrane makes up only a small portion of that, isolation of total 
membranes will produce significant contamination of the plasma membrane by 
proteins from other membranes.18
The most common ways to isolate these internal membrane structures separately is 
to use density gradient centrifugation using some non-ionic gradient material such 
as sucrose.43 The problem with this method is that the plasma membrane does not 
always remain intact. It can take the form of open sheets and vesicles of different 
sizes and may be present in many different gradient fractions recovered during the 
isolation procedure.43
With the objective of obtaining a good plasma membrane sample for proteomic 
analysis, we have evaluated a rarely used literature technique for the isolation of 
plasma membranes, in which a pellicle is formed from cationic colloidal silica.46; 47
This technique uses a suspension of positively charged silica micro beads to coat 
the exterior of cells in culture. These silica beads are electrostatically attracted to 
the exterior of the plasma membranes.46 Once the cells have been covered with 
silica beads, the pellicle is stabilized with long polymers of acrylic acid. This also 
shields the positive charges exposed on the surface of the silica beads. After cells 
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are coated in this manner, they can be lysed and the plasma membranes are easily 
isolated from the rest of the internal membranes because of the increase in their 
density facilitated by the silica. We have modified the published method by addition 
of washing steps after the plasma membranes have been recovered by 
centrifugation.43; 48
This technique works with both suspension cells and cells which require a surface 
or solid support for growth. For cells grown on surfaces, the apical and basolateral 
plasma membrane domains can be isolated separately. By coating the cells still 
adhered to the cell culture flask only the apical plasma membrane is exposed to the 
coating solution and coated. The cells are then lysed while still attached to the 
flasks. Once the cell lysate is removed, the basolateral domains remain attached to 
the cell culture flask, facilitated by the structural proteins which anchor the cells to 
the flask during growth. This can then be cleaned up with a series of stringent 
washes, scraped off of the culture flask, and isolated by centrifugation.48
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B. Materials and Methods
Materials
Criterion precast gels (13.3 x 8.7 cm, 12.5%, 8-16%, and 4-15%), Biosafe Coomassie 
stain, 10x PBS, 10x Tris/Glycine/SDS Buffer, 10x Tris/Glycine Buffer, pre-stained 
protein broad range standards, Laemmli sample buffer, nitrocellulose, and filter paper 
were purchased from Bio-Rad (Hercules, CA) . MgCl2, MES, NaCl, LUDOX-CL 
cationic colloidal silica, polyacrylic acid (100,000 typical molecular weight), 
imidazole, Nycodenz, Na2CO3, EDTA disodium salt, protease inhibitor cocktail, 
ProteoQwest Colorimetric Western Blotting Kit, mouse α-human Na/K ATPase 
primary antibody, DTT, fetal calf serum, and Penicillin-Streptomycin solution were
purchased from Sigma Aldrich (St. Louis, MO). Improved Minimal Essential 
Medium was purchased from American Type Culture Collection (Manassas, VA). 
RPMI 1640 medium was purchased from Invitrogen (Carlsbad, CA). 
Equipment
The Criterion precast gel system, Mini-PROTEAN 3 electrophoresis system, Mini 




The human breast cancer mitoxantrone resistant cell line MCF-7 (MXR MCF-7) was 
a gift from Dr. K. H. Cowan (The Eppley Institute, University of Nebraska Medical 
Center, Omaha, Nebraska) and the human multiple myeloma cell line RPMI 8226 
was a gift from Dr. R. Fenton (The Greenebaum Cancer Center, University of 
Maryland School of Medicine, Baltimore Maryland). MXR MCF-7 cells were grown 
in 150 cm2 cell culture flasks using Improved Minimal Essential Medium containing 
5% fetal calf serum and antibiotics at 37°C and 5% CO2.
49 RPMI 8226 cells were 
grown in the same fashion but using RPMI 1640 media and heat inactivated fetal calf 
serum.50
Preparation of the Plasma Membrane Fraction from Suspension Cell Cultures
Plasma membranes from RPMI 8226 were isolated using a modification of the 
cationic colloidal silica plasma membrane isolation procedure used for suspension 
cells.43; 46 About 1.5g wet weight RPMI 8226 cells were washed in plasma membrane 
coating buffer A (PMCBA – 20 mM MES, 150 mM NaCl, 800 mM sorbitol, pH 5.3) 
and placed drop-wise using a syringe and needle into a 10% suspension of cationic 
colloidal silica in PMCBA.  The suspension was rocked gently on ice for 15 minutes. 
The silica-coated cells were then sedimented at 900g for 5 minutes to remove them 
from the silica solution.
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The silica-coated cells were then washed with PMCBA and sedimented once more at 
900g for 5 minutes to remove any excess silica. The cells were then placed drop-wise,
using a syringe and needle, into a solution of 10mg/ml polyacrylic acid in PMCBA 




Figure 7. Scheme of the coating process using suspension cells. A) Uncoated 
suspension cell. B) Suspension cell coated with cationic silica. C) Suspension cells 
coated with cationic silica, followed by polyacrylic acid.
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The cells were then washed with PMCBA, and placed in lysis buffer with protease 
inhibitors (2.5mM imidazole with Sigma protease inhibitor cocktail) and left on ice 
for 30 minutes to swell the cells. Cells were then lysed using nitrogen cavitation at 
1500 psi. The cell lysate was spun at 900g for 30 min to sediment nuclei and silica 
coated plasma membranes. The pellet was resuspended in lysis buffer, diluted with an 
equal amount of 100% Nycodenz to make a 50% Nycodenz solution and layered over 
70% Nycodenz. Lysis buffer was then layered onto each tube and filled to the top. 
The tubes were spun at 60,000g in an SW60Ti rotor for 23 min. The silica coated 
plasma membranes pellet to the bottom of the tube leaving the nuclei at the 50%/70% 
Nycodenz interface (Figure 8). 
The supernatant was drawn off and the silica coated plasma membrane pellets were 
resuspended in lysis buffer (2.5 mM imidazole pH 7). The pellet was resuspended in 
lysis buffer and centrifuged at top speed on a bench top microfuge to remove the 
excess Nycodenz . The pellet was washed in this same way 2 additional times with 
lysis buffer and 3 times with 100 mM Na2CO3 pH 11.4, for a total of 6 washes. The 
purified plasma membrane proteins were then recovered from their silica coating by 
solubilization directly in Laemmli loading buffer (Bio-Rad), incubation in a 60ºC 
water bath for 30 min, sonication 5 times for 10 seconds at max setting, and 
incubation in a 60ºC water bath for an additional 30 minutes. The suspension was 
then spun at max speed in a bench top centrifuge for 15 min to pellet the silica 
coating from the solubilized plasma membrane proteins. The supernatant, which now 
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Nuclei and Plasma 
Membrane
Nuclei
Figure 8. Scheme for the isolation of the coated plasma membranes from other 
cellular organelles.
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contained the solubilized plasma membrane proteins in the Laemmli buffer, was 
drawn off and stored at -80ºC and the pellet was discarded.
Preparation of the Plasma Membrane Fraction from Cell Culture Monolayers
Plasma membranes from MXR MCF-7 cells growing as monolayers were isolated 
using another modified cationic colloidal silica plasma membrane isolation 
procedure.43; 47  In this case the cells were coated with the silica and polyacrylic acid 
while still attached to the cell culture flasks, so that all washes and cell coating 
solutions were added directly to the flasks with the cells still attached and decanted 
from the flasks to remove. MXR MCF-7 cells were grown to confluence in 150 cm2
cell culture flasks. The media was removed and the cells were washed twice with 
PBS containing 1 mM MgCl2, and 1 mM CaCl2 and then washed with plasma 
membrane coating buffer B (PMCBB - 0.5 mM CaCl2, 1 mM MgCl2, 20 mM MES, 
135 mM NaCl, pH 5.3). The cells were then coated with a 5% suspension of cationic 
colloidal silica in PMCBB and left on ice or on a metal surface in the cold room for 1 
minute. The silica suspension was removed, followed by a wash with PMCBB to 
remove excess silica. The cells were then coated with a 10mg/ml solution of 
polyacrylic acid in PMCBB pH 6-6.5 and left on ice or on a metal surface in the cold 
room for 1 minute. The polyacrylic acid solution was removed, followed by a wash 
with PMCBB to remove any excess polyacrylic acid. The cells were washed once 
quickly with lysis buffer (2.5 mM imidazole pH 7) and then lysis buffer with Sigma 
protease inhibitor cocktail was added to the cell culture flasks, which are left on ice or 
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in the cold room for 30 min to swell the cells. The flasks were then placed on a bench 
top and allowed to reach room temp (~15-30 min). The apical part of the plasma 
membranes (the part of the plasma membrane coated by the silica and polyacrylic 
acid) was sheared from rest of the cell by pipetting the lysis buffer in each flask up 
and down over the cells, or by using a syringe with a long needle to spray the lysis 
buffer directly onto the cells in order to apply enough shearing force to rip off the top 
part of the plasma membranes (Figure 9). 
At this point the apical membranes were drawn off with the pipette-aid and were 
treated as described in the previous section. Following the removal of the nuclei using 
the Nycodenz gradient, the silica coated plasma membrane pellet was washed 3 times 
with lysis buffer. The silica coated plasma membrane sheets were then resuspended in 
30 ml of 100 mM Na2CO3 pH 11.4 in a 50 ml centrifuge tube and placed in a 
sonication bath for 30 minutes with vortexing every 5 minutes. The silica coated 
plasma membrane sheets were pelleted at 16000g in an SW28 rotor for 30 min. The 
pellet was resuspended in 30 ml of 100 mM Na2CO3 pH 11.4 in a 50 ml centrifuge 
tube, sonicated as before and pelleted again in the same fashion. The pellet was then 
resuspended in 1.5 ml of Na2CO3 and spun at maximum speed for 30 min in a 
tabletop microfuge. The apical plasma membrane pellet was solubilized in 2% SDS, 
or directly in Laemmli loading buffer and the plasma membrane proteins were 




Wash away cell debris
Basolateral Membranes
Still Attached to Cell 
Culture Flask
Figure 9. Scheme for the isolation of apical and basolateral plasma membranes from 
cells which require a solid surface for growth.
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At this point the basolateral plasma membranes were still attached to the cell culture 
flasks. Following cell lysis, the cell culture flasks were washed once quickly with 
lysis buffer and then lysis buffer with protease inhibitors was added to each flask and 
left at 4ºC until the previous steps involving the isolation of the apical plasma 
membrane proteins was finished. The flasks were then removed from the cold room 
and incubated for 5 min at room temperature with rocking. The lysis buffer was 
poured off and 5M NaCl was added to each flask and incubated for 5 min at room 
temperature with rocking. The 5M NaCl was poured off and PBS containing 10 mM 
EDTA was added to each flask and incubated for 5 min at room temperature with 
rocking. The PBS/EDTA solution was poured off and washed once quickly with 100 
mM Na2CO3, pH 11.4 to remove any excess PBS/EDTA. One hundred mM Na2CO3, 
pH 11.4 was added to each flask and incubated for 5 min at room temperature with 
rocking. The Na2CO3 was poured off and replaced with fresh 100 mM Na2CO3, pH 
11.4 in each flask. The basolateral plasma membranes were then scraped from the 
bottom of the cell culture flask using a cell scraper and spun at 14,000g in an SW28 
rotor for 20 min. The purified basolateral plasma membranes pellet to the bottom of 
the ultracentrifuge tubes and are then resuspended in a minimal amount of 100 mM 
Na2CO3 and transferred to a 1.5 ml microfuge tube and spun at max speed in a 
microfuge for 20 min to pellet the plasma membranes. The basolateral plasma 
membrane pellet can then be solubilized in 2% SDS or directly in Laemmli loading 
buffer and the plasma membrane proteins were further solubilized using sonication 
and a 60ºC water bath as described above.
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One Dimensional SDS-PAGE and Western Blot Analysis
For Western analysis, 25 µg of protein was loaded onto 12.5% gels and run according 
to specifications using the Bio-Rad Criterion precast gel system. Following 
electrophoresis, the gels were either stained using Bio-Rad Biosafe Coomassie stain 
for protein visualization or left unstained. Following electrophoresis, the proteins on 
the unstained gels were transferred to a nitrocellulose membrane according to 
specifications using the Bio-Rad Mini-PROTEAN 3 electrophoresis system and Mini 
trans-blot cell. Western blotting was done according to specifications using the Sigma 
ProteoQwest Colorimetric Western Blotting Kit and an antibody against the human 
Na/K ATPase was used as the primary antibody. Following electrophoresis and 
western blotting, the stained gels and nitrocellulose were scanned using the Bio-Rad 
GS-800 densitometer. Enrichment of the plasma membrane fractions were quantitated 
from the western blot images using the ImageQuant image analysis software by 
Amersham Biosciences.
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C. Results and Discussion
Western blot experiments were performed to determine the enrichment of the plasma 
membrane fractions isolated with this method using a mouse antibody against human 
Na+/K+ ATPase which is a commonly used plasma membrane marker.43  The relative 
enrichments of each plasma membrane fraction were determined based on the 
densitometry measurement compared to that of the whole cell lysate. By this method, 
plasma membranes were determined to be enriched from RPMI 8226 suspension cells 
18-fold (Figure 10), from the surface bound MXR MCF-7 cells by 8 fold and 20 fold 
for the apical and basolateral domains, respectively (Figure 11). Table 2 shows the 
densitometry data obtained from the Image Quant program. The peak area from the 
densitometry data was used to determine plasma membrane enrichment.
The addition of the wash steps following the plasma membrane isolation increased 
the relative enrichment of plasma membranes when compared to the original method. 
The authors of the earlier paper describing the originally published method used a cell 
suspension of Dictyostelium discoideum, which is a soil living amoeba, and reported 
plasma membrane enrichment levels of 15-17 fold.46   The present method 
reproducibly provides enrichment levels of 18 fold from human myeloma cells 
cultured in suspension.48
The enrichment of the basolateral plasma membrane was greatly increased by the 











Figure 10: Western analysis of RPMI 8226 whole cell lysate and the isolated plasma 

















Figure 11: Western analysis of MCF7 whole cell lysate and the different isolated 
plasma membrane fractions using an antibody against the Na+/K+ ATPase to 




Whole Cell Lysate 218 5




Whole Cell Lysate 138 7
Apical Plasma 
Membrane Fraction 2 1132 76
Basolateral Plasma 
Membranes 2750 115
Table 2: Densitometry data used to determine the enrichment of the isolated plasma 
membrane fractions relative to an unfractionated whole cell lysate. A) Data from the 
Multiple Myeloma cell line. B) Data from the MCF-7 cell line.
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additional wash steps, a factor of 5 over the previously reported method. It has been 
suggested that the basolateral domains, which are not covered with the silica and 
polyacrylic acid, may not attract as much cytoplasmic contamination as their coated 
apical counterparts do due to the electrostatic attraction to the charged silica and 
polyacrylic acid.46 In addition, the basolateral plasma membrane domains are also still 
bound to the cell culture flasks after cell lysis. This enables a series of stringent 
washes to remove most of the unbound cytoplasmic and membrane domain 
contaminants without washing away the sample. After the contaminants are removed, 
the isolated basolateral plasma membrane domains are recovered from the cell culture 
flasks for further analysis.
Recently a novel method for the isolation of plasma membranes has been developed, 
which uses a special reagent containing a biotin subunit linked to a functional group 
that reacts with primary amine groups such as those in the amino acid side chains of 
arginine and lysine.51; 52 Using this technique, cell surface proteins are biotinylated 
before cell lysis. After the cells have been lysed, the plasma membranes are isolated 
using streptavidin immobilized on beads to capture the biotinylated proteins while 
they are still embedded in the plasma membrane. Since this is done in an aqueous 
environment, the membranes remain intact and the plasma membrane can be 
isolated using the biotinylated proteins as anchors for the rest of the membrane. 
This allows plasma membrane proteins, such as those which are only exposed to the 
cytoplasmic face of the plasma membrane, to be isolated even if they were not 
biotinylated as long as they are held firmly in the plasma membrane.
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This method, termed Biotin Directed Affinity Purification (BDAP), achieved a 
comparable level of enrichment as our own, based on the analysis of the proteins 
identified.51 However, there are some potential drawbacks. Our method for the 
isolation of plasma membranes yields both apical and basolateral domains of 
adherent cell cultures, while the BDAP method only isolates the apical plasma 
membrane domains. The BDAP method chemically modifies the lysine and 
arginine amino acid residues of the proteins tagged with this biotin reagent. Since 
these are the trypsin cleavage sites required for proteolytic digestion, there is the 
possibility that this chemical modification may inhibit proteolytic cleavage at these 
sites and reduce the amount of peptides recovered from tryptic digestions. Our 
method involves no covalent modification of the proteins themselves. Only 
electrostatic forces are used and the proteins are eventually recovered unaltered.
Although the silica method was designed for the isolation of plasma membranes from 
cell culture, it should also be effective using fresh tissue samples. After dissociating 
the tissue into individual cells using collagenases and other enzymes to cleave the 
connective proteins between the cells one can isolate their plasma membranes by 
performing the procedure as if they were suspension cell cultures.43; 53 With recent 
advances in primary cell culturing techniques it is possible to isolate and culture 
primary cells directly from a patient and grow them on monolayers and therefore 
isolate the distinct apical and basolateral domains.15; 43; 54
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Chapter 3: Proteomic Analysis of Plasma Membrane 
Proteins
Reproduced in part with permission from: Rahbar, A., Fenselau, C. (2004). 
Integration of Jacobson's Pellicle Method into Proteomic Strategies for Plasma 
Membrane Proteins. J Proteome Res. Web Release Date: 13-Oct-2004. Copyright 
2004 American Chemical Society.
A. Membrane Protein Analysis Overview
The objective of this portion of the experiment was to perform a “bottom-up”
proteomic analysis on the purified plasma membrane protein samples isolated from 
cell cultures in the previous section. The mass spectrometry data collected in this 
experiment was then used for the identification of the proteins present in that 
sample. In order to achieve these results we had to devise a strategy for the 
digestion of the plasma membrane proteins isolated from this fraction into 
individual peptides that can subsequently be analyzed by mass spectrometry. 
Although it is theoretically possible to do a “ top-down” style of analysis for the 
analysis of proteins, that type of proteomic strategy has yet to be applied to the 
identification of membrane proteins.38; 39 The reasons for this include the 
requirement for detergents to keep the membrane proteins in solution, which
interferes with chromatographic separations and mass spectrometry ionization, and 
extensive and heterogeneous carbohydrate modifications found on membrane 
proteins which can significantly alter protein chemistry and diversify molecular 
masses used for identification.55; 56
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There are not as many techniques available for the use in the analysis of membrane 
proteins as there are for soluble proteins. The “shotgun” approach to proteomic 
analysis has had only a minimal amount of success with the analysis of membrane 
proteins. This is primarily due to the fact that the solution digestion of membrane 
proteins is difficult because of the incompatibility of the conditions used for 
enzymatic digestions with the conditions necessary for the solubilization of 
membrane proteins.57 2DGE has obtained only limited success in the separation of 
membrane proteins. This is predominantly due to the inability of the IEF process to 
separate membrane proteins under the conditions used to keep membrane proteins 
in solution.58
Recently there has been a reappearance of the use of 1D SDS-PAGE for protein 
separation and analysis, and this has been especially true in relation to the 
separation of membrane proteins.59; 60 Membrane proteins can be solubilized in SDS 
or Laemmli loading buffer and can subsequently be loaded directly onto SDS-
PAGE gels.48 Although the resolution of this technique is lower than 2DGE, it can 
provide a basic separation of proteins by molecular weight. Once separated, the gel 
bands can be excised from the gel using a razor and subjected to in-gel digestion 
using some digestive enzyme such as trypsin.61  These peptides can then be 
analyzed by MALDI mass spectrometry, with or without LC separations, or 
electrospray mass spectrometry either by direct infusion or coupled to a liquid 
chromatography delivery system. By separating the peptides by liquid 
chromatography before introduction into the mass spectrometer, more peptides can 
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be analyzed from samples of complex peptide mixtures then without separation 
using static infusion experiments.48
B. Materials and Methods
Materials
The Criterion precast gel system, Criterion precast gels (13.3 x 8.7 cm 4-15%), 
Biosafe Coomassie stain, 10x Tris/Glycine/SDS Buffer, pre-stained protein broad 
range standards, and Laemmli sample buffer were purchased from Bio-Rad (Hercules, 
CA) . DTT, iodoacetamide, and TFA were purchased from Sigma Aldrich (St. Louis, 
MO). NH4HCO3, formic acid, acetonitrile, acetic acid, methanol, and CaCl2 were 
purchased from Fisher (Pittsburg, PA). C18 ZipTips were purchased from Millipore 
(Billerica, MA). Modified porcine trypsin was purchased from Promega (Madison, 
WI). 
Equipment
Mass spectra were obtained using an Applied Biosystems Qstar Pulsar i (Foster City, 
CA) with a nanospray ion source from Protana (Odense, Denmark). NanoLC-MS was 
performed online with the LC Packings Ultimate Nano LC System (Sunnyvale, CA). 
NanoES Spray capillaries and an LC-MS head with Liquid Junction were purchased 
from Proxeon (Odense, Denmark). Nanospray emitters were purchased from New 
Objectives (Woburn, MA).
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One Dimensional SDS-PAGE Analysis
Between 40 and 80 µg of plasma membrane protein was loaded onto 4-15% gels and 
run according to manufacturer’s specifications using the Bio-Rad Criterion precast 
gel system. Following electrophoresis, the gels were stained using Bio-Rad Biosafe 
Coomassie stain and the stained gels were scanned using a GS-800 densitometer from 
Bio-Rad (Hercules, CA) .  
Mass Spectrometry
The SDS-PAGE gel was excised into 28 gel bands and tryptic digestion was 
performed on the gel slices.61 After extraction from the gel bands, the tryptic peptides 
were desalted using ZipTip C18 pipette tips. The acetonitrile/TFA was removed using 
a speed vac and the peptides were resuspended in electrospray ionization solution 
(methanol/water/acetic acid - 50/50/2) in preparation for static infusion nanospray 
MS/MS analysis, or placed in 0.1% formic acid (FA) in preparation for nanoLC-
MS/MS analysis. The tryptic peptides were analyzed by static infusion using NanoES 
spray capillaries, and by online nanoLC-MS/MS. Reverse phase conditions were A: 
97.5% H2O/2.5% ACN/0.1%FA, B: 97.5% ACN/2.5% H2O/0.1%FA with a 60 minute 
gradient from 5%-35%B on a PepMap 75µm I.D., 15cm, 3µm, 100Å column from 
LC Packings (Sunnyvale, CA).  
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Protein Identification
Each protein was identified based on sequences from two or more peptides using the 
integrated Qstar software Analyst QS with Bioanalyst and ProID for the LC-MS 
experiments, and the MASCOT search engine from Matrix Science for the offline 
static infusion nanospray experiments.33  The peptides from the static infusion 
experiments were identified with a minimum confidence level of 95%. The peptides 
from the LC-MS experiments were identified with a minimum confidence level of 
99.4% and were also manually sequenced from the tandem mass spectrometry data. 
Figure 12 shows a scheme of the strategy used for the identification of proteins from 
















Figure 12: Strategy for the identification of proteins isolated from the plasma 
membranes of cell cultures.
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C. Results and Discussion
Proteins Identified from RPMI 8226 Multiple Myeloma Cells using Static 
Infusion nanospray Mass Spectrometry
Seventy five µg of plasma membrane proteins isolated from the multiple myeloma 
cell line was loaded onto 4-15% polyacrylamide gels and subjected to SDS-PAGE 
(Figure 13). After protein separation, the gels were stained with Coomassie blue 
stain and cut horizontally into slices 3 mm wide. A total of 28 slices were excised 
from the gel and subjected to in-gel tryptic digestion. The peptides were recovered 
from the gel bands and placed in nanospray ionization solution and analyzed by 
electrospray ionization mass spectrometry without further separation.
Figure 14 shows mass spectra obtained from the analysis of the peptides recovered 
from band 14. Figure 14 A shows a survey scan of the total peptide mixture 
observed from this experiment. When analyzing a complex mixture of peptides 
without any type of separation it is hard to differentiate them from one another. 
Even in the inset it is hard to pick out the doubly charged peptide with a m/z of 
639.3. However when this peptide is selected for tandem mass spectrometry it gives 
excellent fragmentation data and clear sequence tag of “FSDL” can be obtained 
(Figure 14 B). The peptide was found to originate from the neutral amino acid 
transporter B(0) protein (sp|Q15758).
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Figure 13: SDS-PAGE gel of proteins isolated from RPMI 8226 cell cultures. 
Lanes 1-4 contain 75 µg - 12.5 µg of plasma membrane proteins isolated using the 
previously described isolation method for suspension cell cultures. The lane 
containing 75 µg of protein was used for protein identification experiments. Lane 5 is 
25 µg of total proteins isolated from RPMI 8226 without any fractionation, and lane 6 

















Figure 14: A. Survey scan of band 14 excised from an SDS-PAGE gel containing 75 
µg of plasma membrane proteins from RPMI 8226 cells. The inset is an expanded 
view of the 639.3 doubly charged peptide. B. MS/MS scan of the 639.3 doubly 
charged peptide selected for tandem mass spectrometry with the y-ions used to obtain 
the sequence tag labeled above each peak.
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Each of the 28 gel bands excised from the gel was analyzed in the same manner as 
described above. A total of 47 unique proteins were identified from the 28 gel bands 
with a minimum of 2 peptides identified from each protein. Table 3 shows a list of 
the proteins identified from these experiments that have been previously characterized 
as plasma membrane proteins in the literature.
In the previous chapter we showed by Western blot analysis that the plasma 
membranes from RPMI 8226 cell cultures were enriched by 18 fold when compared 
to the abundance levels in the unfractionated whole cell lysate. Here we show that 20 
of the 47 proteins identified from this fraction were identified as plasma membrane 
proteins corresponding to 43% (Figure 15). 
Proteins Identified from MXR MCF-7 Breast Cancer Cells using Static Infusion 
nanospray Mass Spectrometry
Eighty µg of plasma membrane proteins isolated from the basolateral plasma 
membranes of MXR MCF-7 cell line was loaded onto 4-15% polyacrylamide gels 
and subjected to SDS-PAGE and analyzed in the same manner as the myeloma cell 
line (Figure 16). The basolateral plasma membrane fraction was used because the 
enrichment levels were much higher than the apical plasma membrane fraction. 
Figure 17 shows mass spectra obtained from the analysis of the peptides recovered 
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Accession # Protein Name
sp|P05023 Sodium/potassium-transporting ATPase alpha-1 chain precursor  
sp|P08195 4F2 cell-surface antigen heavy chain
sp|Q15758 Neutral amino acid transporter B(0) 
sp|P43007 Neutral amino acid transporter A (SATT) 
sp|Q01650 Large neutral amino acids transporter small subunit 1
sp|Q99808 Equilibrative nucleoside transporter 1
sp|Q14242 P-selectin glycoprotein ligand 1 precursor  
sp|P01891 HLA class I histocompatibility antigen, A-68 alpha chain precursor 
sp|P04898 Guanine nucleotide-binding protein G(i), (Adenylate cyclase-inhibiting G alpha 
protein)
sp|P30685 HLA class I histocompatibility antigen, B-35 B*3505 alpha chain precursor 
sp|P18827 Syndecan-1 precursor  
sp|P54709 Sodium/potassium-transporting ATPase beta-3 chain 
sp|P27105 Erythrocyte band 7 integral membrane protein (Stomatin)
sp|P13761 HLA class II histocompatibility antigen, DR-7 beta chain precursor
sp|P35613 Basigin precursor 
sp|P01903 HLA class II histocompatibility antigen, DR alpha chain precursor 
sp|P25507 Ras-related protein Rab-8 
sp|P01911 HLA class II histocompatibility antigen, DW2.2/DR2.2 beta chain 
sp|O88386 Ras-related protein Rab-10 
sp|Q04941 Intestinal membrane A4 protein
Table 3: Plasma membrane proteins identified from RPMI 8226 multiple myeloma 









Figure 15: Pie chart representing the amount and percentage of plasma membrane 
proteins identified in comparison to the total number of proteins positively identified 
from the plasma membrane fraction isolated from RPMI 8226 cells.
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from band 19. A survey scan of the peptides recovered from band 19 is shown in 
Figure 17 A. The doubly charged peptide with a m/z of 626.7 was manually picked 
for analysis by tandem mass spectrometry and the spectrum is shown in Figure 17 B. 
The amino acid sequence tag “SDFD” can be determined from the fragmented y-ions 
observed. This peptide was found to be from the plasma membrane protein 4F2 cell 
surface antigen (sp|P08195). 
A list of the proteins identified from the basolateral plasma membrane fraction from 
the MXR MCF-7 cell cultures is shown in Table 4. Out of a total of 40 proteins 
identified from this fraction, 20 were found to be plasma membrane proteins (Figure 
18). Although half of the proteins identified were not localized to the plasma 
membrane, this method for the isolation and analysis of plasma membrane proteins 
for both suspension cells and adherent cells worked well enough to identify a 
significant percentage of proteins from the plasma membrane, a subcellular fraction 
which makes up only a tiny portion of the total cell content. 
Proteins Identified from Mitoxantrone Resistant MCF-7 Breast Cancer Cells 
using nanoLC-MS
Our objective for this portion of the experiments was to identify as many proteins as 
possible that were present in the basolateral plasma membrane fraction isolated from 
MXR MCF-7  cells. Inspection of the SDS-PAGE gel experiment used in the static 
nanospray experiments (Figure 16), indicates more than 42 proteins present in the 













Figure 16: SDS-PAGE gel of proteins isolated from basolateral plasma membranes 
from MXR MCF-7 cell cultures. Lane 1, molecular weight standards. Lane 2, 80 µg 
of plasma membrane proteins isolated using the previously described isolation 
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Figure 17: A. Survey scan of band 19 excised from an SDS-PAGE gel containing 80 
µg of plasma membrane proteins from MXR MCF-7 cells. The inset is an expanded 
view of the 626.7 doubly charged peptide. B. MS/MS scan of the 626.7 doubly 
charged peptide selected for tandem mass spectrometry with the y-ions used to obtain 
the sequence tag labeled above each peak.
59
Accession # Protein
sp|P17301 Integrin alpha-2 precursor (Platelet membrane glycoprotein Ia
sp|P06756 Integrin alpha-V precursor (Vitronectin receptor alpha subunit)
sp|P05023 Sodium/potassium-transporting ATPase alpha-1 chain precursor 
sp|P02786 Transferrin receptor protein 2
sp|Q9UNQ0 BCRP, ATP-binding cassette, sub-family G, member 2,  
sp|P08195 4F2 cell-surface antigen heavy chain
sp|Q03113 Guanine nucleotide-binding protein, alpha-12 subunit (G alpha 12) - Homo sapiens (Human).
sp|P11016 Guanine nucleotide-binding protein G(I)
sp|Q01650 Large neutral amino acids transporter small subunit 3
sp|Q00325 Phosphate carrier protein
sp|P16422 Tumor-associated calcium signal transducer 1 precursor 
sp|P21796 Voltage-dependent anion-selective channel protein 1 (VDAC-1)
sp|P60033 CD81 antigen (26 kDa cell surface protein TAPA-1)
sp|P21926 CD9 antigen (P24)
sp|O15551 Claudin-3 (Clostridium perfringens enterotoxin receptor 2)
sp|P51148 Ras-related protein Rab-5C 
sp|P51149 Ras-related protein Rab-7 
sp|Q15286 Ras-related protein Rab-36
sp|O88386 Ras-related protein Rab-10
sp|Q9H0U4 Ras-related protein Rab-1B 
sp|P09526 Ras-related protein Rap-1b 
Table 4: Plasma membrane proteins identified from the basolateral region of MXR 









Figure 18: Pie chart representing the amount and percentage of plasma membrane 
proteins identified in comparison to the total number of proteins positively identified 
from the plasma membrane fraction isolated from MXR MCF-7 cells.
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system coupled to a mass spectrometer to improve the number of protein 
identifications obtained and do so in a high throughput automated way.
Forty µg of plasma membrane proteins isolated from the basolateral plasma 
membranes of MXR MCF-7 cell line was loaded onto 4-15% polyacrylamide gels 
and subjected to SDS-PAGE (Figure 19). Protein gel bands were digested in-gel and 
the peptides were recovered as before. The proteins were then analyzed by nanoLC-
MS in the information dependent acquisition mode.
Figure 20 shows the total ion current (TIC) chromatograms from the LC-MS analysis 
of bands 17 and 19. The gradient profile is from 5 to 35% solvent B over the course 
of 60 min. This allows each of the peptides to be scanned individually without 
interference from other ions of similar m/z values. The gradient does not begin until 
10 min into the analysis and there is approximately 7 min of dead volume between 
the column and the mass spectrometer. The spike in the TIC at 17 min shows the 
switch in solvent flow from the desalting pre-column to the reverse phase nano-
column and represents the beginning of the 60 min gradient (10 min of sample 
equilibration and desalting + 7 min of dead volume). The gradient is then finished at 
77 min on the TIC. At 77 min, only a few of the extremely large hydrophobic 
peptides have yet to be released from the column and they eluted during the period of 
time after this where the solvent B concentration is ramped to 95 %. Most of the 
peptides have eluted from the column at 35% solvent B and it is not necessary to run 
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Figure 19: SDS-PAGE gel of proteins isolated from basolateral plasma membranes 
from MXR and drug susceptible MCF-7 cell cultures. Lane 1 – Molecular weight 
standards. Lane 2 – 40 µg plasma membrane proteins from MXR MCF-7 cells. Lane 
3 – mixture of 20 µg plasma membrane proteins from MXR MCF-7 cells and 20 µg 




Figure 20: Total ion current (TIC) of the LC-MS experiment using A. peptides 
extracted from band 17 of the MXR MCF-7 SDS-PSGE gel and B. peptides extracted 
from band 19 of the MXR MCF-7 SDS-PSGE gel.
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The chromatography performed using the LC-Packing system has excellent resolving 
capability with peak widths of 1 min or less. This provides good signal intensity, 
however the tandem mass spectrometry data must be collected as fast as possible to 
obtain multiple peptide mass measurements. The computer performs a 1 second 
survey scan to identify the m/z and charge states of the peptides to be analyzed, 
followed by 3 MS/MS scans of 3 seconds/scan on the 3 most intense doubly or triply 
charged peptides present. Therefore 1 cycle of this process spans 10 seconds. Once a 
MS/MS mass measurement is made on a peptide of a particular m/z value, that 
particular mass is ignored for 1 minute to make sure that the same 3 most intense 
peaks do not get picked repeatedly while some of the less intense peaks get ignored. 
This process is commonly called dynamic exclusion. 
Figure 21 shows 1 min survey scans from bands 17 and 19. In each of these cases 
the peaks are well resolved with little overlap due to the chromatographic 
separation upstream from the mass spectrometry analysis. The doubly and triply 
charged peptides are selected from these survey scans for 3 second MS/MS scans 
with minimal repetition as explained above. The insets of Figure 21 A and B show 
the expanded views of these survey scans focusing on the 585.8 and 644.8 doubly 
charged peptides.
Due to the limited time window in which peptides eluting from columns can be 
analyzed by the mass spectrometer in LC-MS experiments, computer automation has 






Figure 21: A. Survey scan of the band 17 LC-MS experiment from 53 to 54 min with 
expanded view if the doubly charged 644.8 peptide in the inset spectrum. B. Survey 
scan of the band 19 LCMS experiment from 47.5 to 48.5 min with expanded view if 
the doubly charged 644.8 peptide in the inset spectrum.
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The software used can quickly differentiate between the doubly and triply charged 
peptides, which generate MS/MS spectrum useful for protein identification, and the 
peptides of higher charges, which generate less information rich spectrum and are 
harder to analyze. These programs can also exclude peaks corresponding to non-
peptide species. This ability to differentiate between these types of molecular ions 
allows the mass spectrometer to collect data more efficiently and therefore increase 
the chances for protein identifications.
Computer software is not only critical for the acquisition of data during LC-MS 
experiments but computer algorithms are also indispensable for the analysis of the 
data acquired. Liquid chromatography mass spectrometry experiments can generate 
enormous amounts of data, and especially in the case of a shotgun analysis where 
proteins are digested before any protein separation is performed, many peptides 
from the same protein can be separated across many different fractions. 
Commercial programs can analyze the LC-MS data and recompile it into a list of 
proteins identified from several different experiments.
These automated analyses use sophisticated computer algorithms to obtain protein 
identifications by comparing the experimental MS/MS fragmentation data with the 
theoretical MS/MS fragmentation data of peptides generated from proteins in a 
protein database. This MS/MS ion search combined with any additional information, 
such as the parent peptide molecular weight, the particular enzyme used for the 
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digestion, and species information, if available, is then used to identify which 
protein the peptide originated from. 
Another factor which helps in the automated identification process is the 
identification of immonium ions in the spectrum. Immonium ions are formed by the 
multiple cleavages within the peptide. Each contains an amino group and a side 
chain from an amino acid residue in the peptide. While this information does not 
help in identifying the primary sequence of the peptide, each immonium ion reveals 
the presence of its parent amino acid and consequently aids in the peptide 
identifications by corroborating the presence of the amino acid in the sequence of 
the peptide.
About 10,000 MS/MS scans were performed on peptides automatically selected in 
the LC-MS experiments on the peptides recovered from the in-gel digestion on the 
28 gel bands. Figures 22 and 23 show the results of the automated identification 
from the 585.8 and 644.8 doubly charged peptides shown in Figures 21 A and B
from bands 17 and 19 respectively. 
The upper panes of Figures 22 and 23 show the actual MS/MS fragmentation data 
while the lower panes show theoretical fragmentation data from the peptide 
tentatively identified using the seven ions that occur most frequently when activated 
by low energy multiple collisions. The numbered values are the expected ions 
present based on the identification assigned by the program and the numbers 
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Figure 22:  Automated sequence identification of the doubly charged peptide 585.8 
from band 17 using the integrated Analyst QS software with ProID. Fragment ions 
matching the theoretical fragmentation data are highlighted in yellow.
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Figure 23:  Automated sequence identification of the doubly charged peptide 644.8 
from band 19 using the integrated Analyst QS software with ProID. Fragment ions 
matching the theoretical fragmentation data are highlighted in yellow.
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highlighted in yellow denote experimental values which correspond to theoretical 
values. The predominant species present in the fragmentation data of most of these 
experiments are the b- and y-ions. The resulting peptide identities are assigned 
probability scores in the form of confidence percentages.
The practical application of this technology still requires human interpretation of 
the resulting automated data analysis. This automated analysis of LC-MS data can 
propose multiple protein identifications and a set of parameter restrictions must be 
set to filter out the lower probability hits. All low scoring peptide sequences and 
proteins identified from only 1 peptide identification were excluded from the list of 
proteins identified, no mater what the peptide confidence score. By including only 
peptide identifications of high confidence and only counting protein identifications 
based on 2 or more peptides we can greatly reduce the number of false positives. 
In addition, each protein identification was manually checked. Peptide sequence 
tags were used to manually validate the identity of each of the proteins identified. 
An example of this procedure is shown in Figure 24 A and B. The same peptides 
analyzed using the m/z 585.8 and 644.8 doubly charged ions from bands 17 and 19 
were sequenced manually as is shown in the Figure. The amino acid sequence tags 
“SLLL” and “VSNQ” were identified from the y-ion sequence information and this 
data, along with the name of the enzyme used in the protein cleavage and the parent 
peptide mass, were used to identify the peptides, and subsequently the proteins they 
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Figure 24: A. Amino acid sequence tag “SLLL” obtained manually by sequencing 
the y5 to y9 fragment ions from the 585.8 peptide from band 17. B. Amino acid 
sequence tag “VSNQ” obtained manually by sequencing the y5 to y9 fragment ions 
from the 644.8 peptide from band 19.
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antigen (sp|P08195), and the m/z 644.8 peptide was found to be from the
Transferrin receptor protein 1 (sp|P02786).
One of the strengths of the software is the ability of the program to recompile the 
protein information from many experiments into a summary of all the proteins 
present from many different analyses done over a period of time. Using this 
function we can come up with a protein list of all the proteins identified from all 28 
of our gel bands. Once all of the proteins are manually validated we produce a final 
list of proteins identified. Table 5 shows the list of all proteins identified from the 
basolateral plasma membrane fraction isolated from the MCF-7 cell line along with 
their subcellular location and the number of peptides used to make the identification.
A total of 540 distinct proteins was identified from 3227 unique peptide 
identifications. Figure 25 shows a graphical representation of the subcellular 
locations of each of the proteins as defined by the SwissProt annotation and Gene 
Ontology assignments, along with the number of the 3227 sequenced peptides that 
originate from proteins from the plasma membrane. Figure 26 shows the 100 proteins 
most reliably identified, based on their scores and the number of peptides used to 
make each identification. The 1467 peptides used to identify these 100 proteins 
account for almost half of the peptides sequenced.
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Accession # Protein Name Location # of Peptides
sp|Q00610 Clathrin heavy chain 1 PM 54




sp|P08195 4F2 cell-surface antigen heavy chain PM 33
tr|O75054 Hypothetical protein KIAA0466 Hypo Memb 32
sp|P02786 Transferrin receptor protein 1 PM 31
sp|P20020 Plasma membrane calcium-
transporting ATPase 1
PM 31
sp|P17301 Integrin alpha-2 precursor PM 29
sp|P05787 Keratin, type II cytoskeletal 8 Cytoskeleton 27
sp|P18084 Integrin beta-5 precursor PM 27
tr|Q9UIU0 Dihydropyridine receptor alpha 2 
subunit
PM 25
sp|P13639 Elongation factor 2 (EF-2) Cytoplasm 23
tr|Q8IX16 ATP-binding cassette protein ABCG2 PM 23
sp|P54760 Ephrin type-B receptor 4 precursor PM 21
sp|P10586 LAR protein precursor PM 20
sp|Q9P2B2 Prostaglandin F2 receptor negative 
regulator precursor
PM 20
sp|P05218 Tubulin beta-5 chain Cytoskeleton 19
sp|Q9NZM1 Myoferlin PM 19
sp|O95782 Adapter-related protein complex 2 
alpha 1 subunit
PM 18
sp|P05141 ADP,ATP carrier protein, fibroblast 
isoform 
PM 18
sp|Q14254 Flotillin-2 PM 18
tr|Q7Z3V1 Hypothetical protein DKFZp686D0452 Hypo Memb 17
sp|P01031 Complement C5 precursor Secreted 16
sp|P05217 Tubulin beta-2 chain Cytoskeleton 16
sp|P08069 Insulin-like growth factor I receptor 
precursor
PM 16
sp|P12236 ADP,ATP carrier protein, liver isoform 
T2
Mitochondria 16
sp|P13645 Keratin, type I cytoskeletal 10 Cytoskeleton 16
sp|P55011 Solute carrier family 12 member 2 PM 16




protein glycosyltransferase 67 kDa 
subunit 
ER 15
sp|P05783 Keratin, type I cytoskeletal 18 Cytoskeleton 15
sp|P14618 Pyruvate kinase, M1 isozyme  Cytoplasm 15
sp|P21851 Adapter-related protein complex 2 
beta 1 subunit  
PM 15
sp|P04626 Receptor protein-tyrosine kinase erbB-
2 precursor 
PM 14
sp|P04895 Guanine nucleotide-binding protein PM 14
74
Accession # Protein Name Location # of Peptides
G(S), alpha subunit  
sp|P04899 Guanine nucleotide-binding protein 
G(i), alpha-2 subunit  
PM 14
sp|P50993 Sodium/potassium-transporting 
ATPase alpha-2 chain 
PM 14
sp|Q16720 Plasma membrane calcium-
transporting ATPase 3  
PM 14
tr|Q14433 Guanine nucleotide-binding protein G-
s-alpha-3 
PM 14
tr|Q8TBC0 Similar to GNAS complex locus  PM 14
sp|O00159 Myosin Ic  Cytoplasm 13
sp|P04264 Keratin, type II cytoskeletal 1 Cytoskeleton 13
sp|P07900 Heat shock protein HSP 90-alpha Cytoplasm 13
sp|P27105 Erythrocyte band 7 integral membrane 
protein
PM 13
sp|P35908 Keratin, type II cytoskeletal 2 
epidermal
Cytoskeleton 13
tr|Q8IWA5 CTL2 protein PM 13
tr|Q9UIW2 NOV/plexin-A1 protein PM 13
sp|O94973 Adapter-related protein complex 2 
alpha 2 subunit
PM 12
sp|P01024 Complement C3 precursor Secreted 12
sp|P05209 Tubulin alpha-1 chain Cytoskeleton 12
sp|P12235 ADP,ATP carrier protein, heart PM 12
sp|P24539 ATP synthase B chain, mitochondrial 
precursor
Mitochondria 12
sp|P27824 Calnexin precursor ER 12
sp|P51148 Ras-related protein Rab-5C PM 12
sp|Q13740 CD166 antigen precursor PM 12
sp|Q9BQE3 Tubulin alpha-6 chain Cytoskeleton 12
sp|Q9UL26 Ras-related protein Rab-22A PM 12
sp|Q92508 Hypothetical protein KIAA0233 Hypo Memb 12
tr|Q8WWI5 Choline transporter-like protein 1, 
splice variant a
PM 12
sp|P02304 Histone H4 Nuclei 11
sp|P06576 ATP synthase beta chain, 
mitochondrial precursor
Mitochondria 11
sp|P08238 Heat shock protein HSP 90-beta Cytoplasm 11
sp|P08727 Keratin, type I cytoskeletal 19 Cytoskeleton 11
sp|P20172 Clathrin coat assembly protein AP50 PM 11
sp|P51149 Ras-related protein Rab-7 PM 11
tr|Q9ULH0 Hypothetical protein KIAA1250 Hypo Memb 11
sp|O88386 Ras-related protein Rab-10 PM 10
sp|P02570 Actin, cytoplasmic 1 Cytoskeleton 10
sp|P21796 Voltage-dependent anion-selective 
channel protein 1
PM 10
sp|P35287 Ras-related protein Rab-14 PM 10
sp|Q9H0U4 Ras-related protein Rab-1B PM 10
tr|Q16702 Fatty acid synthase Cytoplasm 10
tr|Q8TD43 Cation channel TRPM4B PM 10
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Accession # Protein Name Location # of Peptides
tr|Q99623 B-cell receptor associated protein Cytoplasm 10
sp|O00161 Synaptosomal-associated protein 23 PM 9
sp|P01111 Transforming protein N-Ras PM 9
sp|P01112 Transforming protein p21 PM 9
sp|P04844 Dolichyl-diphosphooligosaccharide--






sp|P05215 Tubulin alpha-4 chain Cytoskeleton 9
sp|P06733 Alpha enolase Cytoplasm 9
sp|P08754 Guanine nucleotide-binding protein 
G(k), alpha subunit (G(i) alpha-3)
PM 9
sp|P20339 Ras-related protein Rab-5A PM 9
sp|P25705 ATP synthase alpha chain, 
mitochondrial precursor
Mitochondria 9
sp|P35527 Keratin, type I cytoskeletal 9 Cytoskeleton 9
sp|Q15758 Neutral amino acid transporter B(0) 
(ATB(0))
PM 9
sp|Q8TAA9 Vang-like protein 1 PM 9
sp|Q9UJS0 Calcium-binding mitochondrial carrier 
protein Aralar2
PM 9
sp|P17082 Ras-related protein R-Ras2 PM 9
sp|P11717 Cation-independent mannose-6-
phosphate receptor precursor 
PM 8
sp|O75955 Flotillin-1 PM 8
sp|P04406 Glyceraldehyde 3-phosphate 
dehydrogenase, liver
Cytoplasm 8
sp|P08886 Ras-related protein Rab-2A PM 8
sp|P11142 Heat shock cognate 71 kDa protein Cytoplasm 8
sp|P15154 Ras-related C3 botulinum toxin 
substrate 1
PM 8
sp|P16422 Tumor-associated calcium signal 
transducer 1 precursor
PM 8
sp|P16587 ADP-ribosylation factor 3 PM 8
sp|P22392 Nucleoside diphosphate kinase B Nuclei 8
sp|P24410 Ras-related protein Rab-11A PM 8
sp|P26438 ADP-ribosylation factor 6 PM 8
sp|P29316 60S ribosomal protein L23a Ribosome 8
sp|P35232 Prohibitin Cytoplasm 8




sp|Q00325 Phosphate carrier protein, 
mitochondrial precursor
PM 8
sp|Q02978 Mitochondrial 2-oxoglutarate PM 8
sp|Q8WTV0 Scavenger receptor class B member 1 PM 8
sp|Q9NP72 Ras-related protein Rab-18 PM 8
sp|Q9UIQ6 Leucyl-cystinyl aminopeptidase PM 8
tr|Q14160 Hypothetical protein KIAA0147 Hypothetical 8
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Accession # Protein Name Location # of Peptides
tr|Q86X29 Similar to liver-specific bHLH-Zip 
transcription factor
Hypo Memb 8
tr|Q8NE01 Cyclin M3 Membrane 8
tr|Q96AG4 Hypothetical protein (Similar to 
expressed sequence AA959742)
Hypo Memb 8
tr|Q9HCI0 Hypothetical protein KIAA1592 Hypo Memb 8
sp|Q9Y5L3 Ectonucleoside triphosphate 
diphosphohydrolase 2
PM 8
sp|P07947 Proto-oncogene tyrosine-protein 
kinase YES
PM 8
sp|Q14204 Dynein heavy chain, cytosolic Cytoplasm 8
sp|P21333 Filamin A Cytoskeleton 7
sp|O14672 ADAM 10 precursor PM 7
sp|P02278 Histone H2B.a Nuclei 7
sp|P02568 Actin, alpha skeletal muscle Cytoskeleton 7
sp|P04765 Eukaryotic initiation factor 4A-I Cytoplasm 7
sp|P04920 Anion exchange protein 2 PM 7
sp|P06749 Transforming protein RhoA PM 7
sp|P06899 Histone H2B.r Nuclei 7
sp|P08107 Heat shock 70 kDa protein 1 Cytoplasm 7
sp|P08133 Annexin A6 Cytoplasm 7
sp|P09525 Annexin A4 Cytoplasm 7
sp|P17964 Ras-related protein Rap-2b PM 7
sp|P18085 ADP-ribosylation factor 4 PM 7
sp|P20340 Ras-related protein Rab-6A PM 7
sp|P20648 Potassium-transporting ATPase alpha 
chain 1
PM 7
sp|P23396 40S ribosomal protein S3 Ribosome 7
sp|P29312 14-3-3 protein zeta Cytoplasm 7
sp|P33527 Multidrug resistance-associated 
protein 1
PM 7
sp|P35239 Ras-related protein Rab-5B PM 7
sp|P42167 Thymopoietin, isoforms beta Nuclei 7
sp|P50895 Lutheran blood group glycoprotein 
precursor
PM 7
sp|P54753 Ephrin type-B receptor 3 precursor PM 7
sp|P56159 GDNF family receptor alpha 1 
precursor
PM 7
sp|Q01650 Large neutral amino acids transporter 
small subunit 1
PM 7
sp|Q13308 Tyrosine-protein kinase-like 7 
precursor
PM 7
sp|Q14126 Desmoglein 2 precursor PM 7
sp|Q15907 Ras-related protein Rab-11B PM 7
sp|Q9H9B4 Sideroflexin 1 Mitochondria 7
sp|Q9Y277 Voltage-dependent anion-selective 
channel protein 3
Mitochondria 7
sp|Q9Y5M8 Signal recognition particle receptor 
beta subunit
ER 7
tr|O00648 Protein tyrosine phosphatase Hypothetical 7
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Accession # Protein Name Location # of Peptides
PTPCAAX1
tr|O94980 Hypothetical protein KIAA0906 Hypo Memb 7
tr|Q07065 P63 protein Membrane 7
tr|Q7Z7Q4 Tumor-associated calcium signal 
transducer 2
PM 7
tr|Q8NFA6 Transmembrane receptor PTK7-4 PM 7
tr|Q96QB2 Sodium-independent neutral amino 
acid transporter LAT1
PM 7
tr|Q9Y6C9 HSPC032 (Mitochondrial carrier 
homolog 2)
Membrane 7
sp|P02649 Apolipoprotein E precursor Secreted 7
sp|P10643 Complement component C7 precursor Secreted 7
sp|P10113 Ras-related protein Rap-1A PM 7
sp|Q06830 Peroxiredoxin 1 Cytoplasm 7
sp|P07358 Complement component C8 beta 
chain precursor
Secreted 7
sp|O43570 Carbonic anhydrase XII precursor PM 6
sp|O60716 Catenin delta-1 Cytoplasm 6
sp|O75947 ATP synthase D chain, mitochondrial Mitochondria 6
sp|O95858 Tetraspan NET-7 PM 6
sp|P00403 Cytochrome c oxidase polypeptide II Mitochondria 6
sp|P04075 Fructose-bisphosphate aldolase A Cytoplasm 6
sp|P06744 Glucose-6-phosphate isomerase Cytoplasm 6
sp|P07355 Annexin A2 PM 6
sp|P11016 Guanine nucleotide-binding protein 
G(I)
PM 6
sp|P11476 Ras-related protein Rab-1A PM 6
sp|P12259 Coagulation factor V precursor Secreted 6
sp|P23528 Cofilin, non-muscle isoform Cytoskeleton 6
sp|P39656 Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase 48 kDa 
subunit 
ER 6
sp|P45880 Voltage-dependent anion-selective 
channel protein 2
Mitochondria 6
sp|P49411 Elongation factor Tu, mitochondrial 
precursor
Mitochondria 6
sp|P49755 Transmembrane protein Tmp21 
precursor
PM 6
sp|P50395 Rab GDP dissociation inhibitor beta PM 6
sp|Q07020 60S ribosomal protein L18 Ribosome 6
sp|Q12907 Vesicular integral-membrane protein 
VIP36 precursor
ER 6
sp|Q14344 Guanine nucleotide-binding protein, 
alpha-13 subunit
PM 6
sp|Q92542 Nicastrin precursor PM 6
sp|Q9UL25 Ras-related protein Rab-21 PM 6
sp|Q9Y4D1 Disheveled associated activator of 
morphogenesis 1
Cytoplasm 6




Accession # Protein Name Location # of Peptides
tr|Q9BTT5 Similar to NADH dehydrogenase Mitochondria 6
tr|Q9Y639 Stromal cell-derived receptor-1 alpha PM 6
sp|P54707 Potassium-transporting ATPase alpha 
chain 2
PM 6
sp|Q08211 ATP-dependent RNA helicase A Nuclei 6
sp|P08758 Annexin A5 PM 6
sp|O43278 Kunitz-type protease inhibitor 1 
precursor
Secreted 6
sp|P09526 Ras-related protein Rap-1b PM 6
sp|P23284 Peptidyl-prolyl cis-trans isomerase B 
precursor
ER 6
sp|Q9Y4W6 AFG3-like protein 2 Mitochondria 6
sp|P26006 Integrin alpha-3 precursor PM 6
sp|P07339 Cathepsin D precursor Cytoplasm 6
tr|Q7Z341 Hypothetical protein 
DKFZp686J08113
Hypo Memb 5
sp|O14662 Syntaxin 16 (Syn16) Golgi 5
sp|O95292 Vesicle-associated membrane protein-
associated protein
PM 5
sp|O95716 Ras-related protein Rab-3D PM 5
sp|P04901 Guanine nucleotide-binding protein 
G(I)
PM 5
sp|P07996 Thrombospondin 1 precursor PM 5
sp|P10301 Ras-related protein R-Ras PM 5
sp|P10809 60 kDa heat shock protein, 
mitochondrial precursor
Mitochondria 5
sp|P15880 40S ribosomal protein S2 Ribosome 5
sp|P18124 60S ribosomal protein L7 Ribosome 5
sp|P21926 CD9 antigen PM 5
sp|P24407 Ras-related protein Rab-8 PM 5
sp|P25388 Guanine nucleotide-binding protein 
beta subunit-like protein 12.3
PM 5
sp|P26641 Elongation factor 1-gamma Cytoplasm 5
sp|P29992 Guanine nucleotide-binding protein 
G(Y), alpha subunit
PM 5
sp|P35221 Alpha-1 catenin Cytoskeleton 5
sp|P35238 Rho-related GTP-binding protein 
RhoG
PM 5
sp|P35613 Basigin precursor PM 5
sp|P50148 Guanine nucleotide-binding protein 
G(q), alpha subunit
PM 5
sp|P50443 Sulfate transporter PM 5
sp|P51153 Ras-related protein Rab-13 PM 5
sp|P51571 Translocon-associated protein, delta 
subunit precursor
ER 5
sp|P51805 Plexin A3 precursor PM 5
sp|P60033 CD81 antigen PM 5
sp|Q99808 Equilibrative nucleoside transporter 1 PM 5
sp|Q9UBM7 7-dehydrocholesterol reductase ER 5
sp|Q9Y512 SAM50-like protein CGI-51 Mitochondria 5
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sp|Q9Y5Y6 Suppressor of tumorigenicity 14 PM 5
sp|Q9Y624 Junctional adhesion molecule 1 
precursor
PM 5
sp|Q9Y666 Solute carrier family 12 member 7 PM 5
tr|O75396 Vesicle trafficking protein SEC22B ER 5
tr|O75870 PTPsigma Cytoplasm 5
tr|Q7Z5X0 Semaphorin 4C PM 5
tr|Q8IXI1 Rho 2 Mitochondria 5
tr|Q8N271 Hypothetical protein FLJ33856 Hypo Memb 5
tr|Q8NC51 Hypothetical protein FLJ90489 Hypothetical 5
tr|Q8NCB6 Hypothetical protein FLJ90368 Hypo Memb 5
tr|Q8NI87 Phosphoglycerete kinase 1 Cytoplasm 5
tr|Q9BTZ7 Hypothetical protein Hypothetical 5
tr|Q9NX63 Hypothetical protein FLJ20420 Hypothetical 5
tr|Q9UEI6 Polio virus related protein 2, alpha 
isoform
PM 5
sp|O15440 Multidrug resistance-associated 
protein 5
PM 5




sp|P26373 60S ribosomal protein L13 (Breast 
basic conserved protein 1)
Ribosome 5
sp|P27348 14-3-3 protein tau Cytoplasm 5
sp|P46781 40S ribosomal protein S9 Ribosome 5
sp|Q08722 Leukocyte surface antigen CD47 
precursor
PM 5
sp|Q8WXE9 Stonin 2 PM 5
tr|Q8TE01 DERP12 Cytoplasm 5
tr|Q9BSY2 C9orf89 protein Hypo Memb 5
tr|Q9NVJ2 Hypothetical protein FLJ10702 Hypo Memb 5
sp|P07360 Complement component C8 gamma 
chain precursor
Secreted 5
sp|P12931 Proto-oncogene tyrosine-protein 
kinase Src
PM 5
sp|P42655 14-3-3 protein epsilon Cytoplasm 5
sp|Q86UP2 Kinectin ER 5
sp|Q9NRW1 Ras-related protein Rab-6B PM 5
tr|Q7YCE6 Cytochromec oxidase subunit II Mitochondria 5
sp|P00354 Glyceraldehyde 3-phosphate 
dehydrogenase, muscle
Cytoplasm 5
sp|P04720 Elongation factor 1-alpha 1 Cytoplasm 5
sp|P21378 Microsomal signal peptidase 18 kDa 
subunit
PM 5
sp|P29317 Ephrin type-A receptor 2 precursor PM 5
sp|Q05639 Elongation factor 1-alpha 2 Nuclei 5
tr|Q9BTS0 Hypothetical protein Hypo Memb 5
sp|P00338 L-lactate dehydrogenase A chain Cytoplasm 5




Accession # Protein Name Location # of Peptides
sp|O00264 Membrane associated progesterone 
receptor component 1
PM 4
sp|O15439 Multidrug resistance-associated 
protein 4
PM 4
sp|O15551 Claudin-3 PM 4
sp|O95471 Claudin-7 PM 4
sp|P01121 Transforming protein RhoB PM 4
sp|P02261 Histone H2A.c Nuclei 4
sp|P02748 Complement component C9 precursor PM 4
sp|P02768 Serum albumin precursor Secreted 4
sp|P04792 Heat shock 27 kDa protein Cytoplasm 4
sp|P11021 78 kDa glucose-regulated protein 
precursor
ER 4
sp|P11166 Solute carrier family 2, facilitated 
glucose transporter, member 1
PM 4
sp|P13671 Complement component C6 precursor Secreted 4
sp|P15559 NAD(P)H dehydrogenase  1 Cytoplasm 4
sp|P20337 Ras-related protein Rab-3B PM 4
sp|P20700 Lamin B1 Nuclei 4
sp|P22087 Fibrillarin Nuclei 4
sp|P22102 Trifunctional purine biosynthetic 
protein adenosine-3 
Cytoplasm 4
sp|P30050 60S ribosomal protein L12 Ribosome 4
sp|P31930 Ubiquinol-cytochrome C reductase 
complex core protein I
Mitochondria 4
sp|P34897 Serine hydroxymethyltransferase, 
mitochondrial precursor
Mitochondria 4
sp|P48735 Isocitrate dehydrogenase [NADP], 
mitochondrial precursor
Mitochondria 4
sp|P50991 T-complex protein 1, delta subunit Cytoplasm 4
sp|P57088 DB83 protein Hypo Memb 4
sp|Q04721 Neurogenic locus notch homolog 
protein 2 precursor
PM 4
sp|Q13724 Mannosyl-oligosaccharide glucosidase ER 4
sp|Q14118 Dystroglycan precursor PM 4
sp|Q14165 Hypothetical protein KIAA0152 Hypo Memb 4
sp|Q15005 Microsomal signal peptidase 25 kDa 
subunit
PM 4
sp|Q15836 Vesicle-associated membrane protein 
3
PM 4
sp|Q16625 Occludin - Homo sapiens (Human). PM 4
sp|Q8NB49 Potential phospholipid-transporting 
ATPase IG
PM 4
sp|Q9HDC9 Adipocyte plasma membrane-
associated protein
PM 4
tr|O15498 SNARE protein Ykt6 PM 4
tr|O60376 P1.11659_4 Hypo Memb 4
tr|Q14980 Nuclear mitotic apparatus protein 1 Nuclei 4




Accession # Protein Name Location # of Peptides
tr|Q7Z7A6 PPR motif-containing protein Mitochondria 4
tr|Q8IUI5 Similar to butyrate-induced transcript 1 Hypo Memb 4
tr|Q96E39 Similar to RNA binding motif protein, X 
chromosome
Nuclei 4
tr|Q96FY2 Stomatin-like 2 PM 4
tr|Q9H8M5 Hypothetical protein FLJ13417 Hypo Memb 4
sp|O75695 XRP2 protein Cytoplasm 4
sp|P01118 Transforming protein p21b PM 4
sp|P06213 Insulin receptor precursor PM 4
sp|P35214 14-3-3 protein gamma Cytoplasm 4
sp|Q12846 Syntaxin 4 PM 4
sp|Q15286 Ras-related protein Rab-35 PM 4
sp|Q92896 Golgi apparatus protein 1 precursor PM 4
sp|Q9NS69 Mitochondrial import receptor subunit 
TOM22 homolog
Mitochondria 4
sp|O43760 Synaptogyrin 2 PM 4
sp|P04643 40S ribosomal protein S11 Ribosome 4
sp|P05092 Peptidyl-prolyl cis-trans isomerase A Cytoplasm 4
sp|P18621 60S ribosomal protein L17 Ribosome 4
sp|P25232 40S ribosomal protein S18 Ribosome 4
sp|P31946 14-3-3 protein beta Cytoplasm 4
sp|Q04917 14-3-3 protein eta Cytoplasm 4
sp|Q14964 Ras-related protein Rab-39A PM 4
sp|Q9NX76 Chemokine-like factor super family 
member 6
PM 4
tr|O75592 Protein associated with Myc Cytoplasm 4
tr|Q9P134 PRO3078 Cytoplasm 4
sp|P13646 Keratin, type I cytoskeletal 13 Cytoskeleton 4
sp|P29401 Transketolase Cytoplasm 4
sp|P78371 T-complex protein 1, beta subunit Cytoplasm 4
sp|Q14152 Eukaryotic translation initiation factor 3 
subunit 10
Cytoplasm 4
sp|Q92982 Ninjurin 1 PM 4
sp|P12750 40S ribosomal protein S4, X isoform Ribosome 4
sp|P51587 Breast cancer type 2 susceptibility 
protein
Nuclei 4
tr|Q8IWE4 Hypothetical protein MGC48972 Hypothetical 4
tr|Q8NBN2 Hypothetical protein NT2RP2002695 Hypo Memb 4
sp|O75369 Filamin B Cytoskeleton 3
sp|P04114 Apolipoprotein B-100 precursor Secreted 3
tr|Q7Z5D9 Transient receptor potential cation 
channel subfamily M member 4 splice 
variant C
PM 3
sp|O43143 Putative pre-mRNA splicing factor 
RNA helicase
Nuclei 3
sp|O75390 Citrate synthase, mitochondrial 
precursor
Mitochondria 3
sp|O95169 NADH-ubiquinone oxidoreductase 
ASHI subunit, mitochondrial precursor
Mitochondria 3
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sp|P02383 40S ribosomal protein S26 Ribosome 3
sp|P05388 60S acidic ribosomal protein P0 Ribosome 3
sp|P08574 Cytochrome c1, heme protein, 
mitochondrial precursor
Mitochondria 3
sp|P10620 Microsomal glutathione S-transferase 
1
PM 3
sp|P11233 Ras-related protein Ral-A PM 3
sp|P16435 NADPH-cytochrome P450 reductase ER 3
sp|P16991 Nuclease sensitive element binding 
protein 1
Nuclei 3
sp|P17008 40S ribosomal protein S16 Ribosome 3
sp|P25111 40S ribosomal protein S25 Ribosome 3
sp|P32119 Peroxiredoxin 2 Cytoplasm 3
sp|P36578 60S ribosomal protein L4 Ribosome 3
sp|P46776 60S ribosomal protein L27a Ribosome 3
sp|P48047 ATP synthase oligomycin sensitivity 
conferral protein
Mitochondria 3
sp|P50990 T-complex protein 1, theta subunit Cytoplasm 3
sp|P51151 Ras-related protein Rab-9A PM 3
sp|P51659 Peroxisomal multifunctional enzyme 
type 2 
Cytoplasm 3
sp|P53985 Monocarboxylate transporter 1 PM 3
sp|P60174 Triosephosphate isomerase Cytoplasm 3
sp|Q02546 40S ribosomal protein S13 Ribosome 3
sp|Q12931 Heat shock protein 75 kDa, 
mitochondrial precursor
Mitochondria 3
sp|Q14156 Hypothetical protein KIAA0143 Hypo Memb 3
sp|Q14157 Hypothetical protein KIAA0144 Hypothetical 3
sp|Q15365 Poly(rC)-binding protein 1 Nuclei 3
sp|Q15738 NAD(P)-dependent steroid 
dehydrogenase
Cytoplasm 3
sp|Q99714 3-hydroxyacyl-CoA dehydrogenase 
type II
Mitochondria 3
sp|Q9BQE4 Selenoprotein S PM 3
sp|Q9P0L0 Vesicle-associated membrane protein-
associated protein A
PM 3
sp|Q9Y289 Sodium-dependent multivitamin 
transporter
PM 3
tr|O60625 Endobrevin PM 3
tr|O94848 Hypothetical protein KIAA0747 Hypo Memb 3
tr|O94963 Hypothetical protein KIAA0887 Hypothetical 3
tr|O95202 Leucine zipper-EF-hand containing 
transmembrane protein 1
PM 3
tr|O95564 Syntaxin 12 protein PM 3
tr|Q7Z770 Hypothetical protein Hypothetical 3
tr|Q8IUW5 Similar to expressed sequence 
AA536743
Hypo Memb 3
tr|Q8N275 Hypothetical protein FLJ33825 Hypo Memb 3
tr|Q8N2K3 Hypothetical protein FLJ90162 Hypo Memb 3
tr|Q8N4S9 Similar to hypothetical protein Hypo Memb 3
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FLJ30532
tr|Q8N5I2 Similar to hypothetical protein 
CLONE24945
Hypothetical 3
tr|Q8WU20 Suc1-associated neurotrophic factor 
target
PM 3
tr|Q96EQ4 Similar to hypothetical protein, MNCb-
1213
Hypothetical 3
tr|Q96H09 Similar to hypothetical protein 
FLJ10856
Hypo Memb 3
tr|Q96S30 Hypothetical protein gene +108 Hypo Memb 3
tr|Q9NX40 Hypothetical protein FLJ20455 Hypothetical 3
sp|O75131 Copine III Cytoplasm 3
sp|O76062 Delta(14)-sterol reductase PM 3
sp|P00734 Prothrombin precursor Secreted 3
sp|P07741 Adenine phosphoribosyltransferase Cytoplasm 3
sp|P17080 GTP-binding nuclear protein RAN Nuclei 3
sp|P32322 Pyrroline-5-carboxylate reductase Cytoplasm 3
sp|P40616 ADP-ribosylation factor-like protein 1 PM 3
sp|P52907 F-actin capping protein alpha-1 
subunit
Cytoskeleton 3
sp|P53007 Tricarboxylate transport protein, 
mitochondrial precursor
Mitochondria 3
sp|Q13045 Flightless-I protein homolog Cytoskeleton 3
tr|Q9NWS8 Hypothetical protein FLJ20627 Hypothetical 3
sp|P02593 Calmodulin PM 3
sp|P36957 Dihydrolipoamide succinyltransferase 
component of 2-oxoglutarate 
dehydrogenase complex
Mitochondria 3
sp|P49757 Numb protein homolog PM 3
sp|Q8IWT6 Leucine-rich repeat-containing protein 
8 precursor
Hypo Memb 3
sp|Q96S97 Myeloid-associated differentiation 
marker (SB135)
PM 3
sp|Q9NR30 Nucleolar RNA helicase II Nuclei 3
tr|Q9BVV7 Hypothetical protein Hypo Memb 3
sp|P02533 Keratin, type I cytoskeletal 14 Cytoskeleton 3
sp|P06493 Cell division control protein 2 homolog Nuclei 3
sp|P08779 Keratin, type I cytoskeletal 16 Cytoskeleton 3
sp|P10114 Ras-related protein Rap-2a PM 3
sp|P13073 Cytochrome c oxidase subunit IV 
isoform 1, mitochondrial precursor
Mitochondria 3
sp|P16632 40S ribosomal protein S24 Ribosome 3
sp|P17987 T-complex protein 1, alpha subunit Cytoplasm 3
sp|P30519 Heme oxygenase 2 PM 3
sp|Q15375 Ephrin type-A receptor 7 precursor PM 3
sp|Q9NR31 GTP-binding protein SAR1a PM 3
sp|Q9Y6B6 GTP-binding protein SAR1b PM 3
tr|Q86X10 Hypothetical protein KIAA1219 Hypothetical 3
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tr|O75050 Hypothetical protein KIAA0462 Hypothetical 3
tr|Q7Z794 Keratin 1b Cytoskeleton 3
tr|Q8NBP9 Hypothetical protein NT2RP1001023 Hypo Memb 3
sp|O94826 Mitochondrial precursor proteins 
import receptor
Mitochondria 3
sp|P15822 Zinc finger protein 40 Nuclei 3
sp|P18433 Protein-tyrosine phosphatase alpha 
precursor
PM 3
sp|P22455 Fibroblast growth factor receptor 4 
precursor
PM 3
sp|Q02543 60S ribosomal protein L18a Ribosome 3
sp|Q02877 60S ribosomal protein L26 Ribosome 3
sp|Q9BVK6 Glycoprotein 25L2 precursor ER 3
tr|Q86UK0 ABCA12 transporter subfamily A PM 3
sp|O14493 Claudin-4 PM 2
sp|O15126 Secretory carrier-associated 
membrane protein 1
PM 2
sp|O15269 Serine palmitoyltransferase 1 ER 2
sp|O43752 Syntaxin 6 PM 2
sp|O96000 NADH-ubiquinone oxidoreductase 
PDSW subunit
Mitochondria 2
sp|O96008 Probable mitochondrial import 
receptor subunit TOM40 homolog
Mitochondria 2
sp|P00533 Epidermal growth factor receptor 
precursor
PM 2
sp|P00966 Argininosuccinate synthase Cytoplasm 2
sp|P02248 Ubiquitin Cytoplasm 2
sp|P04004 Vitronectin precursor Secreted 2
sp|P07478 Trypsin II precursor Secreted 2
sp|P07737 Profilin I Cytoskeleton 2
sp|P10515 Dihydrolipoamide acetyltransferase 
component of pyruvate 
dehydrogenase complex
Mitochondria 2
sp|P11234 Ras-related protein Ral-B PM 2
sp|P12280 Microsomal signal peptidase 23 kDa 
subunit
ER 2
sp|P13641 Small nuclear ribonucleoprotein Sm 
D1
Nuclei 2
sp|P14625 Endoplasmin precursor ER 2
sp|P17858 6-phosphofructokinase, liver type Cytoplasm 2
sp|P19367 Hexokinase, type I Mitochondria 2
sp|P20674 Cytochrome c oxidase polypeptide Va, 
mitochondrial precursor
Mitochondria 2
sp|P21860 Receptor protein-tyrosine kinase erbB-
3 precursor
PM 2
sp|P22695 Ubiquinol-cytochrome C reductase 
complex core protein 2
Mitochondria 2
sp|P23526 Adenosylhomocysteinase Cytoplasm 2
sp|P25120 60S ribosomal protein L8 Ribosome 2
sp|P31943 Heterogeneous nuclear Nuclei 2
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ribonucleoprotein H
sp|P35222 Beta-catenin Cytoplasm 2
sp|P36542 ATP synthase gamma chain, 
mitochondrial precursor.
Mitochondria 2
sp|P38646 Stress-70 protein, mitochondrial 
precursor
Mitochondria 2
sp|P39026 60S ribosomal protein L11 Ribosome 2
sp|P39030 60S ribosomal protein L15 Ribosome 2
sp|P40926 Malate dehydrogenase, mitochondrial 
precursor
Mitochondria 2
sp|P43307 Translocon-associated protein, alpha 
subunit
ER 2
sp|P48643 T-complex protein 1, epsilon subunit Cytoplasm 2
sp|P49768 Presenilin 1 PM 2
sp|P50402 Emerin Nuclei 2
sp|P50416 Carnitine O-palmitoyltransferase I, 
mitochondrial liver isoform
Mitochondria 2
sp|P51809 Synaptobrevin-like protein 1 PM 2
sp|P57721 Poly(rC)-binding protein 3 Cytoplasm 2
sp|P80723 Brain acid soluble protein 1 PM 2
sp|Q04941 Intestinal membrane A4 protein ER 2
sp|Q07812 Apoptosis regulator BAX, membrane 
isoform alpha
Mitochondria 2
sp|Q10589 Bone marrow stromal antigen 2 PM 2
sp|Q14108 Lysosome membrane protein II PM 2
sp|Q15223 Poliovirus receptor related protein 1 
precursor
PM 2
sp|Q15363 Cop-coated vesicle membrane protein 
p24 precursor
PM 2
sp|Q15366 Poly(rC)-binding protein 2 Nuclei 2
sp|Q15382 GTP-binding protein Rheb PM 2
sp|Q16563 Pantophysin PM 2
sp|Q96HY6 Protein C20orf116 Secreted 2
sp|Q9C0B5 Zinc finger DHHC domain containing 
protein 5
Membrane 2
sp|Q9GZN8 Protein C20orf27 Hypothetical 2
sp|Q9H223 EH-domain containing protein 4 Cytoplasm 2
sp|Q9NRW7 Vacuolar protein sorting-associated 
protein 45
Golgi 2
sp|Q9NUE0 Zinc finger DHHC domain containing 
protein 18
Membrane 2
sp|Q9NY35 Protein C3orf4 Membrane 2
sp|Q9Y282 Serologically defined breast cancer 
antigen NY-BR-84
Membrane 2
sp|Q9Y3E5 Protein CGI-147 Mitochondria 2
tr|O75545 Hypothetical protein Hypo Memb 2
tr|O94843 Hypothetical protein KIAA0739 Hypo Memb 2
tr|O94918 Hypothetical protein KIAA0829 Hypothetical 2
tr|O95164 Hypothetical protein Hypothetical 2
tr|O95297 ZERO related protein PM 2
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tr|Q86UE4 LYRIC/3D3 Hypo Memb 2
tr|Q8NC56 Hypothetical protein FLJ90478 Hypo Memb 2
tr|Q8NC61 Hypothetical protein FLJ90468 Hypo Memb 2
tr|Q8NCL5 Hypotheticalprotein FLJ90173 Hypo Memb 2
tr|Q8WVX9 Similar to RIKEN cDNA 3732409C05 
gene
Hypothetical 2
tr|Q96AZ5 Similar to hypothetical protein 
DKFZp566A1524
Hypothetical 2
tr|Q9BR02 Novel protein similar to RPL23A Ribosome 2
tr|Q9BTZ3 Hypothetical protein Hypothetical 2
tr|Q9BUB7 Similar to hypothetical protein 
FLJ20533
Hypo Memb 2
tr|Q9NWT0 Hypothetical protein Hypothetical 2
tr|Q9Y2G0 Hypothetical protein KIAA0953 Hypothetical 2
sp|O14925 Mitochondrial import inner membrane 
translocase subunit TIM23
Mitochondria 2
sp|P00387 NADH-cytochrome b5 reductase ER 2
sp|P11518 60S ribosomal protein L7a Ribosome 2
sp|P13164 Interferon-induced transmembrane 
protein 1
PM 2
sp|P13987 CD59 glycoprotein precursor PM 2
sp|P59998 ARP2 Cytoskeleton 2
sp|Q15262 Receptor-type protein-tyrosine 
phosphatase kappa precursor
PM 2
tr|Q7Z3D5 Hypothetical protein DKFZp686A1586 Hypo Memb 2
tr|Q8N138 Hypothetical protein FLJ90330 Hypo Memb 2
tr|Q9GZT3 Hypothetical protein PD04872 Hypothetical 2
sp|O43169 Cytochrome b5 outer mitochondrial 
membrane isoform precursor
Mitochondria 2
sp|O75897 Sulfotransferase 1C2 Cytoplasm 2
sp|O75964 ATP synthase g chain, mitochondrial Mitochondria 2
sp|P32969 60S ribosomal protein L9 Ribosome 2
sp|P46977 Oligosaccharyl transferase STT3 
subunit homolog (B5)
PM 2
sp|P56134 ATP synthase f chain, mitochondrial Mitochondria 2
sp|Q13835 Plakophilin 1 Cytoskeleton 2
sp|Q14202 Zinc finger protein 261 Nuclei 2
sp|Q96AX2 Ras-related protein Rab-37 PM 2
sp|Q9Y446 Plakophilin 3 Cytoskeleton 2




sp|O43175 D-3-phosphoglycerate dehydrogenase Cytoplasm 2
sp|O43707 Alpha-actinin 4 Cytoskeleton 2
sp|O75340 Programmed cell death protein 6 Cytoplasm 2
sp|P01270 Parathyroid hormone precursor Secreted 2
sp|P02647 Apolipoprotein A-I precursor Secreted 2
sp|P07237 Protein disulfide isomerase precursor ER 2
sp|P10412 Histone H1.4 Nuclei 2
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sp|P19634 Sodium/hydrogen exchanger 1 PM 2
sp|P21181 Cell division control protein 42 
homolog
PM 2
sp|P54764 Ephrin type-A receptor 4 precursor PM 2
sp|Q13277 Syntaxin 3 PM 2
tr|O14787 Transportin 2 Nuclei 2
tr|Q8N789 Hypothetical protein FLJ25911 Hypo Memb 2
tr|Q9P0N6 Hypothetical protein Hypo Memb 2
sp|P39027 40S ribosomal protein S15a Ribosome 2
tr|Q15290 RB protein binding protein Cytoplasm 2
tr|Q7RTP1 Hypothetical protein Hypothetical 2
tr|Q7Z392 Hypothetical protein 
DKFZp686B15150
Hypothetical 2
tr|Q96F25 Similar to RIKEN cDNA 5430428G01 
gene
Hypo Memb 2
tr|Q9H652 Hypothetical protein FLJ22603 Hypo Memb 2
tr|Q9H6C8 Hypothetical protein FLJ22389 Hypothetical 2
tr|Q9HCF4 Hypothetical protein KIAA1618 Hypothetical 2
tr|O60350 Sodium bicarbonate cotransporter2 Membrane 2
sp|P78504 Jagged 1 precursor PM 2
Table 5: List of protein identified from the basolateral plasma membrane fraction 
isolated from MXR MCF-7 cells. The SwissProt and Trembl accession numbers are 
indicated for each protein. Subcellular Location Abbreviations: PM – plasma 
membrane; Hypo Memb – hypothetical membrane protein; Hypothetical -
hypothetical protein; ER – endoplasmic reticulum; Membrane – membrane protein 
of unspecified location.
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Figure 25: A. Subcellular distribution of proteins identified in the MXR MCF-7 
basolateral plasma membrane fraction. B. The percentage of peptides used for these 
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Figure 26: A. Subcellular distribution of the 100 proteins most reliably identified in 
the MXR MCF-7 basolateral plasma membrane fraction based, on the number of 
peptides used to make the identifications and their scores. B. The percentage of 
peptides used for these top 100 protein identifications which originated from plasma 
membrane proteins.
90
Membrane proteins represent a subset of proteins that are harder to analyze than other 
proteins. Isolation, separation, and digestion are all problematic, especially with 
subcellular fractions such as the plasma membrane which make up so little of the total 
cell content. Designing strategies for the proteomic analysis of membrane 
subfractions often requires non-traditional techniques and procedures. 
Recently there have been some advances in the techniques and procedures of 2DGE 
for the separation of complex protein mixtures, including hydrophobic and membrane 
proteins.62 Although 2DGE can be modified or optimized to resolve and separate 
specific membrane proteins, there does not seem to be one technique that works 
universally for them and so 2DGE is usually excluded as a viable option.38; 39; 58 The 
chemical cleavage agent CNBr has had some success in the cleavage of membrane 
proteins in situ and has also been used in combination with trypsin to increase the 
efficiency of protein digestion. Unfortunately CNBr is dangerous to work with and 
many scientists have tried to find alternatives to using this substance.57
The strength of the method we developed for the proteomic analysis of plasma 
membrane is the improvement in the isolation method. This improved enrichment 
allows for the use of SDS-PAGE for the separation of the proteins.48 Although this 
technique has a much lower resolution than 2DGE, it provides a rudimentary 
separation of membrane proteins by their molecular weight. Once the proteins are 
separated, the gel then provides an environment in which the proteins can be digested. 
The real separation is performed in the LC-MS experiments 
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after the peptides are extracted. This method can also provide excellent sequence 
coverage of the membrane proteins as is shown in Figures 27 and 28.
Of the 540 proteins identified, 214, or 40% of these, have been previously categorized 
as plasma membrane proteins in the literature (Figure 25). There were also many 
plasma membrane associated proteins identified, such as secreted proteins associated 
with the exterior of the plasma membrane (17 proteins, 3%), or cytoskeletal structural 
proteins (30 proteins, 6%) which are strongly associated with the interior of the 
plasma membrane. There were also 73 proteins identified that had not been 
previously identified or reported, and were identified using predicted amino acid 
sequences from human genes. Of these hypothetical proteins, 45 were predicted to 
have transmembrane spanning regions according to the TMHMM program which is 
used to predict transmembrane helices in proteins.63 There was also a small subset of 
proteins that are classified as “Membrane” which were categorized as membrane 
proteins in the literature, but with no subcellular location defined. As shown in 
Figure 26, of the top 100 proteins identified, based on the confidence scores and the 
number of peptides identified from each protein, the majority are from the plasma 
membrane. 
92
Figure 27: The total sequence coverage of the 4F2 cell surface antigen is 59.9%.
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Figure 28: The total sequence coverage of the transferring receptor protein 1 is 
41.4%.
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The protein assignments we use to determine subcellular location were based on the 
information from the databases. Other researchers have reported a higher percentage 
of plasma proteins identified from their isolation, using the Biotin Directed Affinity 
Purification (BDAP) plasma membrane isolation method followed by the same 
technique of SDS-PAGE, in-gel digestion and LC-MS of the recovered peptides.51 A 
closer look at the supplementary results provided by the authors show that they assign 
every membrane protein they encounter as a plasma membrane protein, even proteins 
found exclusively in other organelles such as the ATP synthase protein complex 
found in the mitochondria. Using their criteria, our method would yield a much 
higher enrichment then reported here, but assignments would not be correct. 
Because we provide no experimental results for the assignment of protein subcellular 
locations, we adhere strictly to protein locations reported in the literature. This, 
combined with our requirement for 2 high scoring peptides/protein for identifications, 
and our subsequent manual sequencing provides a very low probability for false 
positives or false assignments of plasma membrane proteins.
Because the plasma membrane sample is highly enriched in relation to the whole cell 
lysate, the low resolution separation technique of SDS-PAGE is sufficiently effective 
to permit the identification of so many plasma membrane proteins. Since we are
isolating the plasma membranes as large sheets with the plasma membrane proteins 
still embedded, we do not have to worry about losing protein due to precipitation in 
protein solubilization steps during the isolation itself. Once the plasma membranes 
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are isolated and washed, they are solubilized directly in SDS solution, followed by 
SDS-PAGE analysis, and this offers minimal opportunity for protein loss.
Protein and peptide sequencing, along with the antibody analysis, suggest that the 
plasma membrane isolation technique is quite effective, and we estimate that of the 
total protein loaded on the gels, over 50% of proteins by mass originate from the 
plasma membrane. Estimating that the plasma membrane makes up about 2-3% of the 
cell mass, and assuming a 20 fold enrichment, the estimated amount of plasma 
membrane protein loaded in the SDS-PAGE experiment would be 40-60% of the total 
protein loaded.  This figure, along with the fact that 51% of the peptides sequenced 
originated from plasma membrane proteins, agrees with our estimation that over 50% 
of our isolated proteins originate from the plasma membrane. 
By performing online nanoLC coupled with mass spectrometry we were able to 
obtain many more protein identifications than by using static infusion nanospray. 
Each of the gel slices contained many proteins so when the peptides were analyzed 
using static infusion nanospray, many of the less abundant peptides that were of 
similar mass to some of the more abundant peptides were not observed. Adding the 
chromatographic separation step allowed the complex peptide mixture to be separated 
and introduced into the mass spectrometer at a slower pace instead of all at once. This 
allowed for the identification of many of the lesser abundant peptides which would 
not normally be observed. 
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Not all of the peptides from the proteins identified are observed during a proteomic 
analysis.64 Peptides containing post translational modifications are more difficult to 
identify then their unmodified counterparts. Identifying these peptides is often tedious 
and typically in a quantitative or qualitative proteomic analysis, these peptides which 
contain post-translational modifications are overlooked.65 This is because 100% 
sequence coverage is not necessary for the identification or relative quantitation of 
proteins in different samples.66; 67; 68; 69; 70
Another reason 100% sequence coverage of proteins is not obtained during proteomic 
analysis is that not all peptides get picked for tandem mass spectrometry during an 
LC-MS experiment. These experiments tend to pick ions with the highest signal 
intensities and if there are many proteins eluting from the column and entering the 
mass spectrometer at the same time, ions with lower intensities from peptides 
abundant in lower levels or from peptides which do not ionize well will often be 
overlooked.71
As was stated previously, we estimate that greater than 50% of the total protein 
loaded onto the SDS-PAGE gels are plasma membrane proteins. Enrichment levels of 
greater than 50% are difficult to obtain when enriching isolating plasma membranes. 
Reasons for this could be that upon cell lysis, membrane components mix with one 
another, thereby increasing the number of membrane proteins identified which are not 
associated with the plasma membrane such as proteins from the ER or Golgi complex. 
Another possible reason for the lower enrichment levels of plasma membranes are 
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that membranes form small vesicles and can capture many of the cytoplasmic proteins 
present during cell lysis. These soluble proteins are then identified and analyzed 
along with the membrane proteins and contribute to the lower enrichment levels. 
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Chapter 4: Comparison of Plasma Membrane Proteins from 
Drug Resistant and Drug Susceptible MCF-7 Breast Cancer 
Cell Lines
Reproduced in part with permission from: Rahbar, A., Fenselau, C. (2004). 
Integration of Jacobson's Pellicle Method into Proteomic Strategies for Plasma 
Membrane Proteins. J Proteome Res. Web Release Date: 13-Oct-2004. Copyright 
2004 American Chemical Society.
A. Comparative Proteomics Techniques
In the previous chapter, we designed a qualitative “bottom-up” proteomic analysis for 
the analysis of plasma membrane proteins from cell cultures. While this information 
is useful for identifying what proteins are present in a particular sample, it does not 
give information on the protein abundance levels of the individual proteins identified. 
Comparative proteomic experiments can be used to obtain information about the 
relative abundance levels of proteins from cells or tissues in different states, such as 
diseased and healthy, treated and untreated, or from different samples altogether. This 
chapter will outline a method developed for comparing the differences in protein 
abundances from proteins from a mitoxantrone resistant (MXR) MCF-7 cell line and 
from a mitoxantrone susceptible, non-resistant parental cell line.
Historically, the first comparative experiments were performed using 2DGE. 
Initially, proteins from 2 different samples would be separated on 2D gels. The 2D 
gel arrays are scanned and the images compared by differential densitometry. 
Protein abundance changes are observes as increased or decreases in gel spot 
densities.49; 72; 73
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Reproducibility among 2D gels from samples originating from the same source is 
usually reasonable and has been improved over time, but becomes more 
problematic when performing comparative studies. Small differences in the way 
proteins are separated on 2D gels can be interpreted as changes in protein 
abundances in comparative studies. This can usually be overcome by running 
multiple gels and averaging the scanned images together. These averaged images 
can then be compared to the averaged images from another sample and these 
averages compared.74 The results from this type of experiment can be dramatic and 
differences in protein abundances can be quickly ascertained. 
A common misconception in the analysis of mass spectrometry data is that there 
exists a relation between the peak intensities and the concentrations of different 
peptides. This is not the case. The ionization efficiencies of peptides differ from one 
peptide to another and are dependent upon the primary structure of individual 
peptides and the chemical properties of the amino acid side chains which make up 
these peptides. Therefore there is no relation between the peptide signal intensities 
from differing peptides.71 That having been said, there is a correlation between the 
peptide signal intensities and the concentrations of identical peptides. 
Recently, alternatives to the gel-based method of comparative analysis have been 
developed using chemical labeling using stable isotopes such as 2H, 13C, 15N, and 
18O.72; 75; 76; 77 Chemical species made up of these stable isotopes contain the same 
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chemical properties as their lighter counterparts but have an increased mass. 
Therefore, if separate peptide mixtures are chemically modified with either light or 
heavy labels, the relative intensities and isotope ratios of each of these species can 
be determined and since the peptides have the same ionization efficiencies, the 
relative abundances of these peptides and therefore the concentrations of the 
proteins they originate from can be measured.
In this study we introduced isotope labels by metabolic labeling, which labels 
proteins during cell growth. Cell cultures are grown in cell culture media containing 
13C6 labeled arginine and lysine residues as the predominant source of these amino 
acids (Figure 29). These amino acids are then incorporated into all newly 
synthesized proteins and all tryptic peptides containing 1 labeled amino acid will 
have masses of 6 Da higher then their unlabeled counterparts. A comparative 
proteomic analysis of proteins from two different cell lines can therefore be 
performed by growing one cell line in normal growth conditions, and growing the 
other cell line in the cell culture media containing the labeled amino acids. The cells 
can then be harvested and the proteins isolated, followed by analysis using mass 
spectrometry. Using this metabolic labeling technique we labeled the proteins from 
a drug susceptible MCF-7 parental cell line using the metabolic labeling technique 
described here and compared the protein abundance changes between it and an 
MCF-7 cell line selected for resistance to mitoxantrone (MXR MCF-7). 
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The role of plasma membrane proteins in drug resistance has been previously studied 
in the mitoxantrone resistant MCF-7 breast cancer cell line.78; 79 It has been shown 
that this cell line does not overexpress P-glycoprotein or any of the proteins from the 
multidrug resistance associated protein family, which are the plasma membrane 
proteins usually associated with multidrug resistance, when compared to the parental 
drug susceptible MCF-7 cell line.80; 81 mRNA analysis and Western immunoassay 
experiments have shown that this cell line overexpresses the ATP-binding cassette 
protein ABCG2 commonly known as breast cancer resistance protein (BCRP), and 
the mechanisms of drug resistance used by this cell line has been shown to be 
independent of the P-glycoprotein and multidrug resistance associated protein 










































Figure 29: Structure of the 13C labeled amino acids arginine and lysine
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B. Materials and Methods
Materials
The Criterion precast gel system, Criterion precast gels (13.3 x 8.7 cm 4-15%), 
Biosafe Coomassie stain, 10x Tris/Glycine/SDS Buffer, pre-stained protein broad 
range standards, and Laemmli sample buffer were purchased from Bio-Rad (Hercules, 
CA) . DTT, iodoacetamide, fetal calf serum, Penicillin-Streptomycin solution, and 
TFA were purchased from Sigma Aldrich (St. Louis, MO). NH4HCO3, formic acid, 
acetonitrile, acetic acid, methanol, and CaCl2 were purchased from Fisher (Pittsburg, 
PA). Modified porcine trypsin was purchased from Promega (Madison, WI). 
Improved Minimal Essential Medium was purchased from American Type Culture 
Collection (Manassas, VA). MEM (Eagle) Media with Earle's Salts without L-lysine 
or L-arginine, and Dialyzed Fetal Bovine Serum was purchased from Atlanta 
Biologicals (Lawrenceville, GA). Carbon-13 (13C) labeled L-lysine and L-arginine 
isotopes at 98% purity was purchased from Cambridge Isotope Laboratories 
(Andover, MA).
Equipment
Mass spectra were obtained using an Applied Biosystems Qstar Pulsar i (Foster City, 
CA) with a nanospray ion source from Protana (Odense, Denmark). NanoLC-MS was 
performed online with the LC Packings Ultimate Nano LC System (Sunnyvale, CA). 
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LC-MS head with Liquid Junction were purchased from Proxeon (Odense, Denmark). 
Nanospray emitters were purchased from New Objectives (Woburn, MA).
Metabolic labeling of the MCF-7 Breast Cancer Cell Line
Metabolically labeled drug susceptible MCF-7 cells were grown using specially 
prepared media. Isotopically labeled L-lysine and L-arginine amino acids were added 
to Minimal Essential Medium lacking the amino acids L-lysine and L-arginine, so 
that the predominant source of biologically usable lysine and arginine are labeled 
with the 13C isotopes. The fetal bovine serum used was made from 25% of the normal 
serum and 75% of the dialyzed serum to minimize the introduction of unlabeled 
lysine and arginine. The labeled MCF-7 cells were grown to confluence using the 
same protocol and growth conditions as the MXR MCF-7 cells, but using the 
modified media and fetal bovine serum specified in place of the normal recipes.
Unlabeled MXR MCF-7 cells were grown using the same conditions as the labeled 
cells but using unlabeled L-arginine and L-lysine in the cell culture media.
One Dimensional SDS-PAGE Analysis
Twenty µg of plasma membrane protein from MXR MCF-7 cells and twenty µg of 
plasma membrane protein from metabolically labeled drug susceptible MCF-7 cells 
were mixed together and loaded onto 4-15% gels and run according to manufacturer’s 
specifications using the Bio-Rad Criterion precast gel system. Following 
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electrophoresis, the gels were stained using Bio-Rad Biosafe Coomassie stain and the 
stained gels were scanned using a GS-800 densitometer from Bio-Rad (Hercules, 
CA) .  
Mass Spectrometry
The SDS-PAGE gel was excised into 28 gel bands and tryptic digestion was 
performed on the gel slices as before.61 After extraction from the gel bands, the 
tryptic peptides were placed in 0.1% formic acid (FA) in preparation for nanoLC-
MS/MS analysis. The tryptic peptides were analyzed by online nanoLC-MS/MS. 
Reverse phase conditions were A: 97.5% H2O/2.5% ACN/0.1%FA, B: 97.5% 
ACN/2.5% H2O/0.1%FA with a 60 minute gradient from 5%-35%B on a PepMap 
75µm I.D., 15cm, 3µm, 100Å column from LC Packings (Sunnyvale, CA).  
Protein Identification
Each protein was identified based on sequences from two or more peptides using the 
integrated Qstar software Analyst QS with Bioanalyst and ProID with a minimum 




Ratios of unlabeled/labeled monoisotopic peak areas were calculated to determine 
protein abundance changes between the two cell lines. Corrections were made in the 
final ratios to compensate for the extent of incorporation determined for the label 
(90%). Ratios ≥ 2 or ≤ 0.5, which correspond to a 100% abundance difference 
between the 2 cell lines, were considered biologically significant and subsequently 
reported. Replicate experiments were performed using mixtures from 4 different 
plasma membrane protein isolations from both unlabeled MXR MCF-7 cells and 
labeled drug susceptible MCF-7 cells. 
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C. Results and Discussion
The technique of metabolic stable isotope labeling involves the incorporation of 
stable isotopes into cells during cell growth so that all newly synthesized 
biomolecules incorporate these isotopes into their chemical structure. Initially this 
was done with single celled organisms such as yeast and bacteria but more recently 
this technique has been successful with cell culture and multicellular organisms such 
as Caenorhabditis elegans, and Drosophila melanogaster. 83; 84; 85; 86; 87; 88
Our lab has developed a technique for the labeling of proteins with both 13C arginine 
and 13C lysine.72 Standard growth conditions for mammalian cell culture uses 90% 
cell culture media and 10% fetal bovine serum. Commercially available cell culture 
media deficient in the amino acids arginine and lysine was mixed with labeled 13C 
arginine and lysine to ensure that the only source of these amino acids is the 13C 
variety. In the initial growth conditions used, dialyzed fetal bovine serum was used to 
minimize the addition of unlabeled 12C arginine and lysine from other proteins or 
peptides in the serum. These conditions resulted in poor cell growth and it was 
subsequently found that cells would grow normally by using 2.5% of the standard 
fetal bovine serum with 7.5% of the dialyzed serum. It is hypothesized that the serum 
contains growth factors necessary for normal growth of these estrogen-positive cells, 
and that the dialyzed serum was most probably deficient in these factors. The 
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Figure 30: 90% incorporation of the labeled amino acids is achieved in the drug 
susceptible MCF-7 breast cancer cell line using the metabolic labeling technique 
developed.
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percentage of incorporation of the labeled amino acids into all newly synthesized 
proteins was determined by the analysis of the mass spectra of the labeled proteins 
alone, along with 1:1 mixtures of labeled and unlabeled proteins from the same MCF-
7 drug susceptible cell line.72 Using this modified recipe, we were able to 
metabolically label the drug susceptible MCF-7 parental cell line with a 90% 
incorporation rate of the 13C amino acids (Figure 30).
The objective of this portion of the study was to determine the differences in the 
abundance levels of proteins from the plasma membranes of mitoxantrone drug 
resistant and drug susceptible MCF-7 cells. Plasma membranes from the two cell 
lines were isolated and the proteins extracted as described in the previous section.
The protein concentrations of these fractions were determined and the plasma 
membrane proteins from the 2 samples were mixed at a 1:1 ratio.  
SDS-PAGE separation of the protein mixture was performed and the gel was 
stained and excised into 28 gel bands.  The gel bands were subjected to in-gel 
tryptic digestion and the peptides were recovered and analyzed by LC-MS. Peptide 
pairs resulting from the in-gel digestions co-eluted and protein quantitation was 
performed using the data obtained. Figure 31 shows a scheme for the procedure 
used for this analysis.
LC-MS was performed on the peptides extracted from the SDS-PAGE gel bands. 
The peptides co-eluted from the reverse phase column and the area under the 
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monoisotopic peaks from the mass spectra of matching labeled and unlabeled 
peptides were compared to each other to determine differences in relative 
abundances of the proteins from the two cell lines. Figure 32 shows an LC-MS 






12C Arg and Lys
MXR MCF-7 Cells








Increased Abundance in 
MXR MCF-7 Cell Line
Increased Abundance in 
Drug Susceptible 
MCF-7 Cell Line
No Change in Abundance
Figure 31: Scheme for the quantitation of protein from the plasma membranes from a  
MXR MCF-7 cell line and a drug susceptible MCF-7 cell line.
112
Figure 32: Labeled and unlabeled peptide pairs extracted from band 22 and analyzed 
by LC-MS. The inset shows an expanded view of the doubly charged peptide 
AGTQLLAGLR from the plasma membrane protein Integrin alpha-V.
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Pairs of labeled and unlabeled peptides were compared for all proteins identified. 
Abundance ratios were determined and the proteins for which changes in abundance 
were more than 100% were reported. Multiple peptides were used for protein 
identification and for calculations for the abundance changes.
Figure 33 shows the labeled and unlabeled peptide pairs used to calculate the relative 
abundances of the 4F2 cell-surface antigen from susceptible and drug resistantMCF-7 
cells. The ratio was calculated for each individual peptide pair and the values are 
averaged in the final results. Table 6 shows the experimental data used to make these 
calculations for the quantitation of the 4F2 cell-surface antigen, a known amino acid 
transporter. 
Changes in the ratios of the intensities of unlabeled/labeled peptides >2 or <0.5 are 
considered significant.  Table 7 lists all of the proteins whose relative abundance 
changes were over 100%. The proteins whose names are in red have higher 
abundances in the MXR MCR-7 cell line, while proteins listed in blue have higher 
abundances in the drug susceptible MCR-7 parental cell line. Figure 34 is a graph 
summarizing the relative abundance changes of the proteins listed in Table 7.
All of the proteins showing abundance changes have been previously identified in the 
literature except for the Hypothetical protein DKFZp686D0452. This protein is 












Figure 33: Peptide pairs from the 4F2 cell surface antigen protein analyzed from the 
labeling experiments.
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EHTK 55569 11347 4.3 4.4 ± 0.3
EDFDSLLQSAK 55125 10589 4.6
IGDLQAFQGHGAGNL
AGLK 266680 55646 4.2
LDYLSSLK 232940 43462 4.7
WCSWSLSQAR 45220 9689 4.1
Table 6: Data used to calculate the abundance changes between the plasma
membrane protein 4F2 cell surface antigen isolated from the unlabeled MXR MCF-7 
cell line and the 13C labeled drug susceptible MCF-7 cell line using the areas of the 
monoisotopic peaks from each peptide.
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Accession # Protein Name Ratio MXR MCF-7 /MCF-7 
tr|Q8IX16
ATP- binding cassette protein ABCG2
(BCRP) Not Detected in MCF-7 Cells
sp|P02786 Transferrin receptor protein 1 Not Detected in MCF-7 Cells
sp|Q01650
Large neutral amino acids transporter 
small subunit 1 7.9 ± 0.6
tr|Q9UIU0
Dihydropyridine receptor alpha 2 
subunit 6.8 ± 0.4
sp|P08195 4F2 cell-surface antigen heavy chain 4.4 ± 0.3
sp|Q00610 Clathrin heavy chain 1 3.7 ± 0.4
sp|P04895
Guanine nucleotide-binding protein 
G(S), alpha subunit  3.5 ± 0.3
sp|P27105
Erythrocyte band 7 integral membrane 
protein 2.6 ± 0.3
sp|P54760 Ephrin type-B receptor 4 2.3 ± 0.3
sp|P17301 Integrin alpha-2 0.33 ± 0.03
tr|Q7Z3V1 Hypothetical protein DKFZp686D0452 0.3 ± 0.02
sp|P11166
Solute carrier family 2, facilitated 
glucose transporter, member 1 0.25 ± 0.02
tr|Q7Z7Q4
Tumor-associated calcium signal 
transducer 2 0.24 ± 0.08
sp|Q14344
Guanine nucleotide-binding protein, 
alpha-13 subunit 0.085 ± 0.01
sp|P26006 Integrin alpha-3 0.073 ± 0.006
Table 7: Protein abundance changes found when comparing the plasma membrane 
sub-proteomes of the unlabeled MXR MCF-7 breast cancer cell line and the 13C 
























Difference in Abundance 
sp|P26006 Integrin alpha-3
sp|Q14344 Guanine nucleotide-binding protein, alpha-13 subunit
tr|Q7Z7Q4 Tumor-associated calcium signal transducer 2
sp|P11166 Solute carrier family 2, facilitated glucose transporter, member 1
tr|Q7Z3V1 Hypothetical protein DKFZp686D0452
sp|P17301 Integrin alpha-2
sp|P54760 Ephrin type-B receptor 4
sp|P27105 Erythrocyte band 7 integral membrane protein
sp|P04895 Guanine nucleotide-binding protein G(S), alpha subunit  
sp|Q00610 Clathrin heavy chain 1
sp|P08195 4F2 cell-surface antigen heavy chain
tr|Q9UIU0 Dihydropyridine receptor alpha 2 subunit
sp|Q01650 Large neutral amino acids transporter small subunit 1
sp|P02786 Transferrin receptor protein 1
tr|Q8IX16 ATP-binding cassette protein ABCG2 (BCRP)
Figure 34: Graph showing the relative changes in abundance of protein levels. The 
numbers represent relative fold increases in abundance levels with respect to the 
ratios of MXR MCF-7 protein abundance/ drug susceptible MCF-7 protein 
abundances. Positive values represent proteins whose abundance is higher in MXR 
MCF-7 cells and negative abundances represent proteins whose abundance is higher 
in the drug susceptible MCF-7 cell line.
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with the integrin beta-1 subunit. The proteins summarized in Table 7 can be 
classified into 4 different groups:
1. Cell Adhesion Proteins
• Integrin alpha-2 
• Integrin alpha-2 
• Hypothetical protein DKFZp686D0452 (beta integrin)
2. Transport Proteins
• ATP-binding cassette protein ABCG2 (BCRP)
• Solute carrier family 2, facilitated glucose transporter, member 1
• 4F2 cell-surface antigen heavy chain
• Large neutral amino acids transporter small subunit 1
3. Proteins involved in Receptor Mediated Endocytosis
• Transferrin receptor protein 1
• Clathrin heavy chain 1
4. Signal Transduction Proteins and Receptors
• Guanine nucleotide-binding protein, alpha-13 subunit
• Guanine nucleotide-binding protein G(S), alpha subunit  
• Erythrocyte band 7 integral membrane protein
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• Ephrin type-B receptor 4
• Dihydropyridine receptor alpha 2 subunit
• Tumor-associated calcium signal transducer 2
The goal of this study was to identify the differences in protein abundances between 
the 2 cell lines and to use this data to elucidate the possible mechanisms of drug 
resistance for the MXR MCF-7 cell line. At first glance, the proteins listed in Table 
7 seem unrelated. The protein functions range from structural to the transport of 
materials and information.
The most well known contributor to drug resistance is the drug efflux protein P-
glycoprotein (P-gp).7 This protein is localized in the plasma membrane of cells and 
its mechanism involves ATP-dependant transport of materials out of the cell. This 
results in the reduction of intracellular accumulation of many types of anticancer 
drugs.7; 8; 9 Although this is one of the most common causes of multidrug resistance, 
this protein was not detected in either cell line studied.
One of the major differences observed in the present study is the presence of the 
breast cancer resistance protein (BCRP), also called the ATP-binding cassette 
protein ABCG2. This protein is present in the MXR MCF-7 cell line but was not 
detected in the drug susceptible cell line. BCRP was first discovered in the
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multidrug resistant breast cancer cell line MCF-7/AdrVp.78 This cell line was 
selected by culturing MCF-7 cells in the presence of increasing amounts of 
adriamycin and verapamil.89 Cells in which drug resistance is induced using 
doxorubicin have been found to overexpress the protein P-gp.72; 73; 90; 91 Verapamil 
is an inhibitor of P-gp and by growing MCF-7 cells in the presence of both 
doxorubicin and verapamil, a different mechanism of resistance is achieved, which 
includes the overexpression of BCRP. 
Like P-gp, BCRP is an ATP-driven efflux pump found in the plasma membrane.  It 
has some substrates in common with P-gp and therefore can also facilitate multidrug 
resistance. Transfection of the drug susceptible MCF-7 cell line with an expression 
vector containing the full length BCRP cDNA clone resulted in cells which were 
resistant to mitoxantrone, daunorubicin, and doxorubicin, indicating that the 
overexpression of BCRP alone was enough to confer drug resistance.78
Like BCRP, transferrin receptor protein 1 was found in the MXR MCF-7 cell line but 
not detected in the drug susceptible cell line. Transferrin receptor protein 1 is 
responsible for the receptor mediated endocytosis of transferrin into the cell.92; 93
Each transferrin protein binds 2 molecules of iron. Iron bound transferrin binds to 
transferrin receptor protein 1 and initiates uptake into the cell. This is the major 
mechanism for iron uptake by cells.92
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Although an increase in transferrin receptor protein 1 or intracellular transferrin has 
not been associated with drug resistance, perhaps the increase in iron uptake by the 
cell is useful in an indirect way. Many proteins in the cell require iron in order to 
function properly. Proteins from the cytochrome P450 class of proteins contain a 
heme group and require iron for proper substrate binding. This class of proteins are 
classified as phase I detoxifying enzymes and have been previously shown to be a 
common mechanism of drug resistance.7; 13; 14; 94 An increase in the intracellular
expression of these enzymes would explain the benefit of increased uptake of iron. 
Clathrin abundance was increased by almost 4 fold in the MXR MCF-7 cell line. 
Clathrin is a protein used in the receptor mediated endocytosis process, and an 
increase in the abundance of this protein at the plasma membrane could be associated 
with an increase in the endocytosis process. 
Guanine nucleotide-binding proteins, or G-proteins, are heterotrimeric proteins made 
up of 3 different subunits, called alpha, beta, and gamma. These proteins are located 
on the cytoplasmic face of the plasma membrane. The Guanine nucleotide-binding 
protein, alpha-13 subunit, was found to have almost a 12 fold decrease in abundance 
in the MXR MCF- 7 cell line. This protein has not been previously associated with 
drug resistance, however it has been previously identified as an activator of 
apoptosis.95; 96 Blocking of the apoptotic pathway is one way that drug resistance can 
be achieved, so this may be another mechanism used to achieve drug resistance by the 
MXR MCF-7 cell line.
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The 4F2 cell-surface antigen heavy chain and large neutral amino acid transporter 
small subunit 1 proteins were both shown to be present in higher abundance in the 
MXR MCF-7 cell line. These proteins form heterodimers in the plasma membrane 
and are responsible for the uptake of amino acids into the cell. Since these proteins 
require both subunits for proper function, it makes sense that if there was an increase 
in the abundance of one of these proteins, the other would be increased also. 
Although the increase in these proteins has not yet been shown to confer drug 
resistance, it has been suggested that an increase in the expression of these 2 proteins 
would provide a selection advantage over other cells in the body because the cell 
would be able to survive in a nutrient restricted environment.97
Out of the six proteins whose abundances are lower in the MXR MCF-7 cell line, 3 
of them are classified as integrins. Integrins are transmembrane spanning proteins 
which are responsible for the attachment of cells to extracellular matrix and cell-to-
cell adhesion.98; 99 They have a single transmembrane region and a large 
extracellular domain. They form heterodimers made up of alpha and beta subunits, 
both of which are required for proper function. Although there has been no data 
suggesting that a change in the abundance of integrins has any effect on drug 
resistance, there is data suggesting that changes in the expression of integrins can be 
responsible for metastasis and the spreading of tumor cells to other parts of the 
body through the circulatory system.100; 101
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The erythrocyte band 7 integral membrane protein, also know as stomatin, showed 
an increase in abundance in the resistant cell line. Although the function of this 
protein is not known, it has been shown to associate with the glucose transporter 
solute carrier family 2, facilitated glucose transporter, member 1, also known as 
GLUT-1. 102; 103These proteins co-immunoprecipitated with one another, suggesting
that they physically interact in a complex.102; 103 An increase in the expression of 
stomatin has also been associated with a decrease in the levels of glucose transport 
into the cell, without a decrease in the levels of GLUT-1 protein.102; 103 In our 
experiments, we observed an increase in stomatin levels, but also a decrease in 
GLUT-1 levels. So here we have two different processes that potentially decrease 
intracellular levels of glucose. A decreased glucose level has not been associated 
with drug resistance, and is surprising in view of the energy needs of cancer cells.
Tumor-associated calcium signal transducer 2 is a cell surface receptor, which is 
widely expressed in human cancers.104; 105 Its abundance was 4 fold lower in the 
MXR MCF-7 cell line, but its function and ligand are unknown. The 
dihydropyridine receptor alpha 2 subunit is a voltage gated calcium channel protein 
which had an increase in abundance in the MXR MCF-7 cell line. Both of these 
proteins appear to be involved in intracellular calcium signaling, but no link 
between these proteins has been reported and their function in relation to drug 
resistance is not immediately apparent.
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The ephrin type-B receptor 4 and the guanine nucleotide-binding protein G(S), 
alpha subunit both have increased abundances in the MXR MCF-7 cell line. These 
proteins are both involved in signal transduction and other downstream signaling 
events. Unfortunately, without information on changes in protein concentrations in 
the interior of the cell, e.g., for the tumor-associated calcium signal transducer 2, 
and the dihydropyridine receptor alpha 2 subunit, the role of these membrane 
proteins is too general to determine their purpose in drug resistance.
Although the role played in drug resistance by the last four proteins discussed could 
not be surmised, functions of 11 of the 15 proteins of interest have been reasonably 
proposed. Nine of these have been reported by others to be related to drug 
resistance, metastasis, or increased resistance to harsh environments provided by 
the increase in the efficiency in nutrient uptake.
Of the 15 proteins exhibiting significant abundance changes, only BCRP has been 
previously reported as being associated with drug resistance.106 It is suggested in this 
dissertation that by decreasing the abundance of guanine nucleotide-binding protein 
alpha-13 subunit, perhaps the tumor cell can increase its chances for survival while 
being treated with an anti-cancer agent by blocking one of the pathways leading to 
apoptosis and therefore achieving drug resistance. It is also suggested here that the 
purpose of increasing the abundance of transferrin receptor protein 1, and therefore 
increasing the intercellular concentration of iron, is to supply iron containing 
detoxifying enzymes, such as the cytochrome P450 family of proteins, with the iron 
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needed for proper function. The increase in detoxification enzymes has been linked 
with an increase in drug resistance.7
This dissertation suggests that at least one, and as many as three, mechanisms of drug 
resistance are achieved by the mitoxantrone drug resistant MCF-7 breast cancer cell 
line. As was stated earlier, the overexpression of BCRP alone is enough to confer 
drug resistance.78 In the absence of further information on protein abundances within 
the cell, there is no way to determine whether guanine nucleotide-binding protein 
alpha-13 subunit, or transferrin receptor protein 1 are involved in drug resistance or 
some other process altogether. However, information about protein abundance 
differences can still be of use. 
The overexpression of transferrin receptor protein 1 has been used for several 
different types of therapies. Researchers have been able to introduce reagents into 
cells by exploiting the transferrin receptor mediated endocytosis pathway. Transferrin 
binds many other metals besides iron and by complexing metals with therapeutic 
agents, these agents can be brought into the cell in this manner.107 Anticancer agents 
have also been introduced into tumor cells by conjugating them to transferrin and the 
agents are therefore brought into the cell along with transferrin during Endocytosis.107
The overexpression of transferrin receptor protein 1 has also been used in gene 
therapy. Transferrin proteins can be synthesized containing long polylysine tails. 
These polylysine tails bind to plasmid DNA and this plasmid DNA is then brought 
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into the cell during the endocytosis of transferrin. Using this technique, researchers 
can introduce foreign genes into different systems.108
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Conclusions and Prospectus
Mass spectrometry has established itself as an important analytical tool with many 
functions. It is used for the rapid detection and characterization of microorganisms 
and this use may someday be a vital tool in the defense against bio-terrorism and 
important for national security.109 It is commonly used for the identification and 
analysis of proteins from complex biological systems.41; 110 It can be used in 
combination with stable isotope labeling and differential densitometry techniques to 
determine relative protein abundance changes between separate samples.73; 75 It can 
also be used (in combination with HPLC) in metabolic profiling experiments to 
determine the products formed from the breakdown of molecules through metabolic 
pathways.111
The methods improved upon and developed in this dissertation can be used to 
increase the understanding of the mechanisms and biological processes which occur 
in the plasma membrane. The plasma membrane is a major focal point for research in 
the area of drug design and targeted therapies, and although there is a significant 
amount of interest by biotechnology and pharmaceutical companies in the proteins 
found in the plasma membrane, relatively little is known about it due to the analytical 
challenges in isolation and separation. 
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Proteins identified can be used for identifying protein markers for early disease 
detection.112 The information gained can also be used to design targeted therapies for 
the treatment of cancer and other diseases.113 Information about protein expression in 
different disease states can help to elucidate the mechanisms of disease progression 
along with the causes of disease.
With the increases in the technology and advances in automation and bioinformatics, 
mass spectrometry may some day be used in doctors’ offices for routine diagnostics 
and health examinations. Miniaturization of mass spectrometers and the decreases in 
instrument cost may allow routine screening of blood samples using the proteins from
blood plasma or tissue biopsies taken from patients and this information could be 
critical for early diagnosis. 
The improved method we developed for the isolation of plasma membranes in 
combination with mass spectrometry and proteomics allowed us to identify many 
proteins found in the plasma membrane.48 The high level of plasma membrane 
enrichment achieved on the front end of the experiments allows for a much more 
detailed downstream analysis. This isolation method can almost be thought of as a 
first dimension of separation. Over 95% of the cellular components are separated, 
creating a fraction which is much less complex then the whole cell lysate. Combining 
this sub-cellular fractionation along with separation by SDS-PAGE and LC-MS 
provided a detailed analysis of the proteins from the plasma membrane. 
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Our experiments have shown that this technique works with both suspension cell 
culture and adherent cell cultures. The technique should also be transferable to tissue 
sample analysis and primary cell lines.53; 54 Information obtained from this type of 
analysis may eventually be used to diagnose the presence and type of cancer in 
individual patients and can also be used to determine the mechanisms involved in 
drug resistance as is discussed in this dissertation.
The technique of in vivo metabolic labeling of cells in culture using stable isotopes 
allows proteins to be labeled prior to cell lysis.72 Typically, proteins or peptides are 
labeled after cell lysis and the isolation of the desired protein fraction. By labeling 
during cell growth, as described in this dissertation, sample loss can be reduced due to 
the decrease in sample handling. 
In closing, this dissertation outlines a method for the isolation, identification, and 
quantitation of plasma membrane proteins isolated from cell cultures. The 
information obtained from these types of comparative proteomic analyses can help to 
elucidate the mechanisms involved in drug resistance.
130
References
1. Kochanek, K. D. & Smith, B. L. (2004). Deaths: preliminary data for 2002. 
Natl Vital Stat Rep 52, 1-47.
2. Edwards, B. K., Howe, H. L., Ries, L. A., Thun, M. J., Rosenberg, H. M., 
Yancik, R., Wingo, P. A., Jemal, A. & Feigal, E. G. (2002). Annual report to 
the nation on the status of cancer, 1973-1999, featuring implications of age 
and aging on U.S. cancer burden. Cancer 94, 2766-92.
3. Brenner, B., Ilson, D. H. & Minsky, B. D. (2004). Treatment of localized 
esophageal cancer. Semin Oncol 31, 554-65.
4. Chagpar, A. B. (2004). Advances in the management of localized breast 
cancer: an overview. J Ky Med Assoc 102, 202-8.
5. Hurria, A. & Kris, M. G. (2003). Management of lung cancer in older adults. 
CA Cancer J Clin 53, 325-41.
6. Hurley, L. H. (2002). DNA and its associated processes as targets for cancer 
therapy. Nat Rev Cancer 2, 188-200.
7. Gottesman, M. M., Fojo, T. & Bates, S. E. (2002). Multidrug resistance in 
cancer: role of ATP-dependent transporters. Nat Rev Cancer 2, 48-58.
8. Ling, V., Gerlach, J. & Kartner, N. (1984). Multidrug resistance. Breast 
Cancer Res Treat 4, 89-94.
9. Scotto, K. W. & Johnson, R. A. (2001). Transcription of the multidrug 
resistance gene MDR1: a therapeutic target. Mol Interv 1, 117-25.
10. Karwatsky, J. M. & Georges, E. (2004). Drug binding domains of MRP1 
(ABCC1) as revealed by photoaffinity labeling. Curr Med Chem Anti-Canc 
Agents 4, 19-30.
11. Donnelly, J. G. (2004). Pharmacogenetics in cancer chemotherapy: balancing 
toxicity and response. Ther Drug Monit 26, 231-5.
12. Townsend, D. M. & Tew, K. D. (2003). The role of glutathione-S-transferase 
in anti-cancer drug resistance. Oncogene 22, 7369-75.
13. McFadyen, M. C., McLeod, H. L., Jackson, F. C., Melvin, W. T., Doehmer, J. 
& Murray, G. I. (2001). Cytochrome P450 CYP1B1 protein expression: a 
131
novel mechanism of anticancer drug resistance. Biochem Pharmacol 62, 207-
12.
14. McFadyen, M. C., Melvin, W. T. & Murray, G. I. (2004). Cytochrome P450 
CYP1B1 activity in renal cell carcinoma. Br J Cancer  91, 966-71.
15. Howbrook, D. N., van der Valk, A. M., O'Shaughnessy, M. C., Sarker, D. K., 
Baker, S. C. & Lloyd, A. W. (2003). Developments in microarray 
technologies. Drug Discov Today 8, 642-51.
16. Templin, M. F., Stoll, D., Schrenk, M., Traub, P. C., Vohringer, C. F. & Joos, 
T. O. (2002). Protein microarray technology. Trends Biotechnol 20, 160-6.
17. Ashurst, J. L. & Collins, J. E. (2003). Gene annotation: prediction and testing. 
Annu Rev Genomics Hum Genet 4, 69-88.
18. Kearney, P. & Thibault, P. (2003). Bioinformatics meets proteomics--bridging 
the gap between mass spectrometry data analysis and cell biology. J 
Bioinform Comput Biol 1, 183-200.
19. Dreger, M. (2003). Subcellular proteomics. Mass Spectrom Rev 22, 27-56.
20. Srinivas, K. S., Chandrasekar, G., Srivastava, R. & Puvanakrishnan, R. (2004). 
A novel protocol for the subcellular fractionation of C3A hepatoma cells 
using sucrose density gradient centrifugation. J Biochem Biophys Methods 60, 
23-7.
21. Thomson, J. J. (1897). Cathode Rays. Philos Mag 44, 293.
22. Karas, M. & Hillenkamp, F. (1988). Laser desorption ionization of proteins 
with molecular masses exceeding 10,000 daltons. Anal Chem 60, 2299-301.
23. Karas, M. & Kruger, R. (2003). Ion formation in MALDI: the cluster 
ionization mechanism. Chem Rev 103, 427-40.
24. Tanaka, K. W., H.; Ido, Y.; Akita, S.; Yoshida, Y.; Yoshida, T.,. (1988). 
Protein and Polymer Analyses up to m/z 100 000 by Laser Ionization Time-of 
flight Mass Spectrometry. Rapid Commun. Mass Spectrom 2, 151-153.
25. Fenn, J. B., Mann, M., Meng, C. K., Wong, S. F. & Whitehouse, C. M. (1989). 
Electrospray ionization for mass spectrometry of large biomolecules. Science
246, 64-71.
26. Whitehouse, C. M., Dreyer, R. N., Yamashita, M. & Fenn, J. B. (1985). 
Electrospray interface for liquid chromatographs and mass spectrometers. 
Anal Chem 57, 675-9.
132
27. Vertes, A. (1991). Laser desorption of large molecules: mechanisms and 
models. In Methods and mechanisms for producing ions from large molecules
(Ens, K. G. S. a. W., ed.), pp. 275-286. Plenum Press, New York.
28. Vertes, A. I., G. Gijbels, R. (1993). Hydrodynamic model of matrix assisted 
laser desorption mass spectrometry. Anal Chem 65, 2389-2393.
29. Yamashita, M. F., J. (1984). J Phys Chem 88, 4451-4459.
30. Alexandrov, M. G., L. Krasnov, V.  Nikolaev, V. Pavlenko, V. Shkurov, V. 
(1984). Dokl Akad Nauk SSSR 227, 379-383.
31. VerBerkmoes, N. C., Bundy, J. L., Hauser, L., Asano, K. G., Razumovskaya, 
J., Larimer, F., Hettich, R. L. & Stephenson, J. L., Jr. (2002). Integrating "top-
down" and "bottom-up" mass spectrometric approaches for proteomic analysis 
of Shewanella oneidensis. J Proteome Res 1, 239-52.
32. Cottrell, J. S. (1994). Protein identification by peptide mass fingerprinting. 
Pept Res 7, 115-24.
33. Perkins, D. N., Pappin, D. J., Creasy, D. M. & Cottrell, J. S. (1999). 
Probability-based protein identification by searching sequence databases using 
mass spectrometry data. Electrophoresis 20, 3551-67.
34. Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of 
the head of bacteriophage T4. Nature 227, 680-5.
35. Williams, S. D. & David, S. S. (1998). Evidence that MutY is a 
monofunctional glycosylase capable of forming a covalent Schiff base 
intermediate with substrate DNA. Nucleic Acids Res 26, 5123-33.
36. Segrest, J. J., R. (1972). Molecular weight determination of glycoproteins by 
polyacrylamide gel electrophoresis in sodium dodecyl sulfate. In Methods 
Enzymol, Vol. 28B, pp. 54-63.
37. Hames, B. (1990). One-dimensional polyacrylamide gel electrophoresis. In 
Gel electrophoresis of Proteins: A practical approach 2nd Edition edit. 
(Hames, B. a. R., D., ed.). Oxford University Press, New York.
38. Wu, C. C. & Yates, J. R., 3rd. (2003). The application of mass spectrometry to 
membrane proteomics. Nat Biotechnol 21, 262-7.
39. Wu, C. C., MacCoss, M. J., Howell, K. E. & Yates, J. R., 3rd. (2003). A 
method for the comprehensive proteomic analysis of membrane proteins. Nat 
Biotechnol 21, 532-8.
133
40. Santoni, V., Molloy, M. & Rabilloud, T. (2000). Membrane proteins and 
proteomics: un amour impossible? Electrophoresis 21, 1054-70.
41. Washburn, M. P., Wolters, D. & Yates, J. R., 3rd. (2001). Large-scale analysis 
of the yeast proteome by multidimensional protein identification technology. 
Nat Biotechnol 19, 242-7.
42. Alberts, B. B., D. Lewis, J. Raff, M. Roberts, K. Watson, J. (1994). 
Membrane Structure. In Molecular Biology of the Cell, pp. 446-506. Garland 
Publishing, New York.
43. Spector, D. L. G., R.D.; Leinwand, L.A. (1998). Cells : A Laboratory Manual. 
Culture and Biochemical Analysis of Cells (Spector, D. L. G., R.D.; Leinwand, 
L.A, Ed.), 1. 3 vols, Cold Spring Harbor Laboratory Press, Cold Spring 
Harbor.
44. Ramsby, M. L. & Makowski, G. S. (1999). Differential detergent fractionation 
of eukaryotic cells. Analysis by two-dimensional gel electrophoresis. Methods 
Mol Biol 112, 53-66.
45. Molloy, M. P., Herbert, B. R., Walsh, B. J., Tyler, M. I., Traini, M., Sanchez, 
J. C., Hochstrasser, D. F., Williams, K. L. & Gooley, A. A. (1998). Extraction 
of membrane proteins by differential solubilization for separation using two-
dimensional gel electrophoresis. Electrophoresis 19, 837-44.
46. Chaney, L. K. & Jacobson, B. S. (1983). Coating cells with colloidal silica for 
high yield isolation of plasma membrane sheets and identification of 
transmembrane proteins. J Biol Chem 258, 10062-72.
47. Stolz, D. B. & Jacobson, B. S. (1992). Examination of transcellular membrane 
protein polarity of bovine aortic endothelial cells in vitro using the cationic 
colloidal silica microbead membrane-isolation procedure. J Cell Sci 103 ( Pt 
1), 39-51.
48. Rahbar, A. Fenselau, C. (2004). Integration of Jacobson's Pellicle Method into 
Proteomic Strategies for Plasma Membrane Proteins. J Proteome Res in press.
49. Hathout, Y., Riordan, K., Gehrmann, M. & Fenselau, C. (2002). Differential 
protein expression in the cytosol fraction of an MCF-7 breast cancer cell line 
selected for resistance toward melphalan. J Proteome Res 1, 435-42.
50. Dvorakova, K., Waltmire, C. N., Payne, C. M., Tome, M. E., Briehl, M. M. & 
Dorr, R. T. (2001). Induction of mitochondrial changes in myeloma cells by 
imexon. Blood 97, 3544-51.
134
51. Zhao, Y., Zhang, W. & Kho, Y. (2004). Proteomic analysis of integral plasma 
membrane proteins. Anal Chem 76, 1817-23.
52. Shin, B. K., Wang, H., Yim, A. M., Le Naour, F., Brichory, F., Jang, J. H., 
Zhao, R., Puravs, E., Tra, J., Michael, C. W., Misek, D. E. & Hanash, S. M. 
(2003). Global profiling of the cell surface proteome of cancer cells uncovers 
an abundance of proteins with chaperone function. J Biol Chem 278, 7607-16.
53. Schuurman, B., Beelen, R. H., Heuff, G., Scheper, R. J., Claessen, A. M. & 
Meyer, S. (1995). Fresh colorectal tumor cells isolated from individual 
patients differ in their susceptibility to monocyte mediated cytotoxicity. J 
Surg Oncol 60, 18-23.
54. Dunfield, L. D., Shepherd, T. G. & Nachtigal, M. W. (2002). Primary culture 
and mRNA analysis of human ovarian cells. Biol Proced Online 4, 55-61.
55. Kellam, B., De Bank, P. A. & Shakesheff, K. M. (2003). Chemical 
modification of mammalian cell surfaces. Chem Soc Rev 32, 327-37.
56. Martin-Rendon, E. & Blake, D. J. (2003). Protein glycosylation in disease: 
new insights into the congenital muscular dystrophies. Trends Pharmacol Sci
24, 178-83.
57. Blonder, J., Conrads, T. P., Yu, L. R., Terunuma, A., Janini, G. M., Issaq, H. 
J., Vogel, J. C. & Veenstra, T. D. (2004). A detergent- and cyanogen bromide-
free method for integral membrane proteomics: application to Halobacterium 
purple membranes and the human epidermal membrane proteome. Proteomics
4, 31-45.
58. Rabilloud, T. (2003). Membrane proteins ride shotgun. Nat Biotechnol 21, 
508-10.
59. Simpson, R. J., Connolly, L. M., Eddes, J. S., Pereira, J. J., Moritz, R. L. & 
Reid, G. E. (2000). Proteomic analysis of the human colon carcinoma cell line 
(LIM 1215): development of a membrane protein database. Electrophoresis
21, 1707-32.
60. Adam, P. J., Boyd, R., Tyson, K. L., Fletcher, G. C., Stamps, A., Hudson, L., 
Poyser, H. R., Redpath, N., Griffiths, M., Steers, G., Harris, A. L., Patel, S., 
Berry, J., Loader, J. A., Townsend, R. R., Daviet, L., Legrain, P., Parekh, R. 
& Terrett, J. A. (2003). Comprehensive proteomic analysis of breast cancer 
cell membranes reveals unique proteins with potential roles in clinical cancer. 
J Biol Chem 278, 6482-9.
135
61. Jensen, O. N., Wilm, M., Shevchenko, A. & Mann, M. (1999). Sample 
preparation methods for mass spectrometric peptide mapping directly from 2-
DE gels. Methods Mol Biol 112, 513-30.
62. Luche, S., Santoni, V. & Rabilloud, T. (2003). Evaluation of nonionic and 
zwitterionic detergents as membrane protein solubilizers in two-dimensional 
electrophoresis. Proteomics 3, 249-53.
63. Krogh, A., Larsson, B., von Heijne, G. & Sonnhammer, E. L. (2001). 
Predicting transmembrane protein topology with a hidden Markov model: 
application to complete genomes. J Mol Biol 305, 567-80.
64. Blonder, J., Terunuma, A., Conrads, T. P., Chan, K. C., Yee, C., Lucas, D. A., 
Schaefer, C. F., Yu, L. R., Issaq, H. J., Veenstra, T. D. & Vogel, J. C. (2004). 
A proteomic characterization of the plasma membrane of human epidermis by 
high-throughput mass spectrometry. J Invest Dermatol 123, 691-9.
65. Blonder, J., Rodriguez-Galan, M. C., Chan, K. C., Lucas, D. A., Yu, L. R., 
Conrads, T. P., Issaq, H. J., Young, H. A. & Veenstra, T. D. (2004). Analysis 
of murine natural killer cell microsomal proteins using two-dimensional liquid 
chromatography coupled to tandem electrospray ionization mass spectrometry. 
J Proteome Res 3, 862-70.
66. Blonder, J., Hale, M. L., Lucas, D. A., Schaefer, C. F., Yu, L. R., Conrads, T. 
P., Issaq, H. J., Stiles, B. G. & Veenstra, T. D. (2004). Proteomic analysis of 
detergent-resistant membrane rafts. Electrophoresis 25, 1307-18.
67. Brown, K. J. & Fenselau, C. (2004). Investigation of doxorubicin resistance in 
MCF-7 breast cancer cells using shot-gun comparative proteomics with 
proteolytic 18O labeling. J Proteome Res 3, 455-62.
68. Turecek, F. (2002). Mass spectrometry in coupling with affinity capture-
release and isotope-coded affinity tags for quantitative protein analysis. J 
Mass Spectrom 37, 1-14.
69. Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., Gelb, M. H. & Aebersold, R. 
(1999). Quantitative analysis of complex protein mixtures using isotope-coded 
affinity tags. Nat Biotechnol 17, 994-9.
70. Schmidt, F., Donahoe, S., Hagens, K., Mattow, J., Schaible, U. E., Kaufmann, 
S. H., Aebersold, R. & Jungblut, P. R. (2004). Complementary analysis of the 
Mycobacterium tuberculosis proteome by two-dimensional electrophoresis 
and isotope-coded affinity tag technology. Mol Cell Proteomics 3, 24-42.
136
71. Krause, E., Wenschuh, H. & Jungblut, P. R. (1999). The dominance of 
arginine-containing peptides in MALDI-derived tryptic mass fingerprints of 
proteins. Anal Chem 71, 4160-5.
72. Gehrmann, M. H., Y. Fenselau, C. (2004). Evaluation of Metabolic Labeling 
for Comparative Proteomics in Breast Cancer Cells. J Proteome Res In press.
73. Gehrmann, M. L., Fenselau, C. & Hathout, Y. (2004). Highly altered protein
expression profile in the adriamycin resistant MCF-7 cell line. J Proteome Res
3, 403-9.
74. Shefcheck, K., Yao, X. & Fenselau, C. (2003). Fractionation of cytosolic 
proteins on an immobilized heparin column. Anal Chem 75, 1691-8.
75. Yao, X., Freas, A., Ramirez, J., Demirev, P. A. & Fenselau, C. (2001). 
Proteolytic 18O labeling for comparative proteomics: model studies with two 
serotypes of adenovirus. Anal Chem 73, 2836-42.
76. Jiang, H. & English, A. M. (2002). Quantitative analysis of the yeast proteome 
by incorporation of isotopically labeled leucine. J Proteome Res 1, 345-50.
77. Vogt, J. A., Schroer, K., Holzer, K., Hunzinger, C., Klemm, M., Biefang-
Arndt, K., Schillo, S., Cahill, M. A., Schrattenholz, A., Matthies, H. & 
Stegmann, W. (2003). Protein abundance quantification in embryonic stem 
cells using incomplete metabolic labelling with 15N amino acids, matrix-
assisted laser desorption/ionisation time-of-flight mass spectrometry, and 
analysis of relative isotopologue abundances of peptides. Rapid Commun 
Mass Spectrom 17, 1273-82.
78. Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K. 
& Ross, D. D. (1998). A multidrug resistance transporter from human MCF-7 
breast cancer cells. Proc Natl Acad Sci U S A 95, 15665-70.
79. Zhang, S., Yang, X. & Morris, M. E. (2004). Flavonoids are inhibitors of 
breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol
65, 1208-16.
80. Doyle, L. A. & Ross, D. D. (2003). Multidrug resistance mediated by the 
breast cancer resistance protein BCRP (ABCG2). Oncogene 22, 7340-58.
81. Lee, J. S., Scala, S., Matsumoto, Y., Dickstein, B., Robey, R., Zhan, Z., 
Altenberg, G. & Bates, S. E. (1997). Reduced drug accumulation and 
multidrug resistance in human breast cancer cells without associated P-
glycoprotein or MRP overexpression. J Cell Biochem 65, 513-26.
137
82. Robey, R. W., Medina-Perez, W. Y., Nishiyama, K., Lahusen, T., Miyake, K., 
Litman, T., Senderowicz, A. M., Ross, D. D. & Bates, S. E. (2001). 
Overexpression of the ATP-binding cassette half-transporter, ABCG2 
(Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin 
Cancer Res 7, 145-52.
83. Oda, Y., Huang, K., Cross, F. R., Cowburn, D. & Chait, B. T. (1999). 
Accurate quantitation of protein expression and site-specific phosphorylation. 
Proc Natl Acad Sci U S A 96, 6591-6.
84. Conrads, T. P., Alving, K., Veenstra, T. D., Belov, M. E., Anderson, G. A., 
Anderson, D. J., Lipton, M. S., Pasa-Tolic, L., Udseth, H. R., Chrisler, W. B., 
Thrall, B. D. & Smith, R. D. (2001). Quantitative analysis of bacterial and 
mammalian proteomes using a combination of cysteine affinity tags and 15N-
metabolic labeling. Anal Chem 73, 2132-9.
85. Ong, S. E., Blagoev, B., Kratchmarova, I., Kristensen, D. B., Steen, H., 
Pandey, A. & Mann, M. (2002). Stable isotope labeling by amino acids in cell 
culture, SILAC, as a simple and accurate approach to expression proteomics. 
Mol Cell Proteomics 1, 376-86.
86. Ong, S. E., Kratchmarova, I. & Mann, M. (2003). Properties of 13C-
substituted arginine in stable isotope labeling by amino acids in cell culture 
(SILAC). J Proteome Res 2, 173-81.
87. Everley, P. A., Krijgsveld, J., Zetter, B. R. & Gygi, S. P. (2004). Quantitative 
cancer proteomics: stable isotope labeling with amino acids in cell culture 
(SILAC) as a tool for prostate cancer research. Mol Cell Proteomics 3, 729-35.
88. Krijgsveld, J., Ketting, R. F., Mahmoudi, T., Johansen, J., Artal-Sanz, M., 
Verrijzer, C. P., Plasterk, R. H. & Heck, A. J. (2003). Metabolic labeling of C. 
elegans and D. melanogaster for quantitative proteomics. Nat Biotechnol 21, 
927-31.
89. Chen, Y. N., Mickley, L. A., Schwartz, A. M., Acton, E. M., Hwang, J. L. & 
Fojo, A. T. (1990). Characterization of adriamycin-resistant human breast 
cancer cells which display overexpression of a novel resistance-related 
membrane protein. J Biol Chem 265, 10073-80.
90. Mealey, K. L., Barhoumi, R., Burghardt, R. C., Safe, S. & Kochevar, D. T. 
(2002). Doxycycline induces expression of P glycoprotein in MCF-7 breast 
carcinoma cells. Antimicrob Agents Chemother 46, 755-61.
91. Hall, J. G., Cory, A. H. & Cory, J. G. (1999). Lack of competition of 
substrates for P-glycoprotein in MCF-7 breast cancer cells overexpressing 
MDR1. Adv Enzyme Regul 39, 113-28.
138
92. Qian, Z. M., Li, H., Sun, H. & Ho, K. (2002). Targeted drug delivery via the 
transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 54, 561-
87.
93. Aisen, P. (2004). Transferrin receptor 1. Int J Biochem Cell Biol 36, 2137-43.
94. Lewis, D. F. (2004). 57 varieties: the human cytochromes P450. 
Pharmacogenomics 5, 305-18.
95. Berestetskaya, Y. V., Faure, M. P., Ichijo, H. & Voyno-Yasenetskaya, T. A. 
(1998). Regulation of apoptosis by alpha-subunits of G12 and G13 proteins 
via apoptosis signal-regulating kinase-1. J Biol Chem 273, 27816-23.
96. Althoefer, H., Eversole-Cire, P. & Simon, M. I. (1997). Constitutively active 
Galphaq and Galpha13 trigger apoptosis through different pathways. J Biol 
Chem 272, 24380-6.
97. Campbell, W. A. & Thompson, N. L. (2001). Overexpression of LAT1/CD98 
light chain is sufficient to increase system L-amino acid transport activity in 
mouse hepatocytes but not fibroblasts. J Biol Chem 276, 16877-84.
98. Lee, J. W. & Juliano, R. (2004). Mitogenic signal transduction by integrin-
and growth factor receptor-mediated pathways. Mol Cells 17, 188-202.
99. Jin, H. & Varner, J. (2004). Integrins: roles in cancer development and as 
treatment targets. Br J Cancer 90, 561-5.
100. Felding-Habermann, B., O'Toole, T. E., Smith, J. W., Fransvea, E., Ruggeri, Z. 
M., Ginsberg, M. H., Hughes, P. E., Pampori, N., Shattil, S. J., Saven, A. & 
Mueller, B. M. (2001). Integrin activation controls metastasis in human breast 
cancer. Proc Natl Acad Sci U S A 98, 1853-8.
101. Meyer, A., van Golen, C. M., Kim, B., van Golen, K. L. & Feldman, E. L. 
(2004). Integrin expression regulates neuroblastoma attachment and migration. 
Neoplasia 6, 332-42.
102. Zhang, J. Z., Hayashi, H., Ebina, Y., Prohaska, R. & Ismail-Beigi, F. (1999). 
Association of stomatin (band 7.2b) with Glut1 glucose transporter. Arch 
Biochem Biophys 372, 173-8.
103. Zhang, J. Z., Abbud, W., Prohaska, R. & Ismail-Beigi, F. (2001). 
Overexpression of stomatin depresses GLUT-1 glucose transporter activity. 
Am J Physiol Cell Physiol 280, C1277-83.
139
104. Mangino, G., Grazia Capri, M., Barnaba, V. & Alberti, S. (2002). Presentation 
of native TROP-2 tumor antigens to human cytotoxic T lymphocytes by 
engineered antigen-presenting cells. Int J Cancer 101, 353-9.
105. Ripani, E., Sacchetti, A., Corda, D. & Alberti, S. (1998). Human Trop-2 is a 
tumor-associated calcium signal transducer. Int J Cancer 76, 671-6.
106. Yanase, K., Tsukahara, S., Asada, S., Ishikawa, E., Imai, Y. & Sugimoto, Y. 
(2004). Gefitinib reverses breast cancer resistance protein-mediated drug 
resistance. Mol Cancer Ther 3, 1119-25.
107. Lodish, H. B., Arnold; Zipursky, S. Lawrence; Matsudaira, Paul; Baltimore, 
David; Darnell, James E. (1999). Protein Sorting: Organelle Biogenesis and 
Protein Secretion. In Molecular Biology of the Cell 4th ed. edit., Vol. Chapter 
17. W. H. Freeman & Co, New York.
108. Strachan, T. a. R. & P., A. (1999). Gene therapy and other molecular genetic-
based therapeutic approaches. In Human Molecular Genetics 2 2nd ed. edit., 
Vol. Chapter 22. BIOS Scientific Publishers Ltd, Oxford, UK.
109. Yao, Z. P., Afonso, C. & Fenselau, C. (2002). Rapid microorganism 
identification with on-slide proteolytic digestion followed by matrix-assisted 
laser desorption/ionization tandem mass spectrometry and database searching. 
Rapid Commun Mass Spectrom 16, 1953-6.
110. Cargile, B. J., Bundy, J. L., Freeman, T. W. & Stephenson, J. L., Jr. (2004). 
Gel based isoelectric focusing of peptides and the utility of isoelectric point in 
protein identification. J Proteome Res 3, 112-9.
111. Guttman, A., Varoglu, M. & Khandurina, J. (2004). Multidimensional 
separations in the pharmaceutical arena. Drug Discov Today 9, 136-44.
112. Rai, A. J. & Chan, D. W. (2004). Cancer proteomics: Serum diagnostics for 
tumor marker discovery. Ann N Y Acad Sci 1022, 286-94.
113. Dyba, M., Tarasova, N. I. & Michejda, C. J. (2004). Small molecule toxins 
targeting tumor receptors. Curr Pharm Des 10, 2311-34.
